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CHAPTER I 
 
STATEMENT OF THE PROBLEM 
 
Female life expectancy in the United States has steadily increased and 
now averages 81 years, meanwhile the age at which women reach 
menopause remains constant at 51 years. Therefore, women live over one 
third of their life in a post-menopausal, low estrogenic state. Both neurological 
and cardiovascular disorders increase following menopause, affecting 
women’s quality of life and leading to large health care costs. 
 Various epidemiological and basic science studies show that estrogen 
administration (Estrogen Therapy (ET)) can have neuroprotective effects and 
improve cognitive abilities in aging women, as well as reduce heart disease 
and overall mortality. The Women’s Health Initiative (WHI), a large clinical 
study conducted in menopausal women, had contradicting conclusions but 
established that age is an important factor in determining positive or negative 
outcome of ET. This led to the formulation of the “Timing Hypothesis”: 
exposure to estrogens is beneficial for younger women but has detrimental 
outcomes in post-menopausal women who have experienced an extensive 
hypo-estrogenic period. While its underlying mechanisms are unclear, it is 
well accepted that the female brain and heart respond differently to ET before 
and after menopause, indicating that cellular and molecular components in 
these tissues undergo some kind of modification during the perimenopausal 
transition.  
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The effects of estrogen are mediated by two high affinity nuclear 
receptors, Estrogen Receptor α (ERα) and Estrogen Receptor β (ERβ) and 
the G-protein coupled estrogen receptor1 (GPER) . Evidence supports that 
ERβ plays an important role in neuroprotection and cardioprotection, but 
aspects of ERβ molecular signaling are still not fully understood. One 
possibility is that aging and estrogen deprivation alter ERβ post translational 
modifications, such as phosphorylation. Indeed the mitogen activated protein 
kinases (MAPKs) responsible for phosphorylation of ERβ have been shown to 
be modulated by aging and steroid hormones. The goal of my dissertation is 
to determine the consequences of ERβ phosphorylation and how prolonged 
estrogen deprivation prior to estrogen treatment alters MAPKs signaling in the 
brain and heart.
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CHAPTER II 
LITERATURE REVIEW 
ESTROGEN SYNTHESIS AND MENOPAUSE 
 
Estrogens are the primary female sex hormones; they are mostly 
produced by the ovaries, corpus luteum and placenta in premenopausal 
women [1]. A smaller amount of estrogens is also produced by non gonadal 
organs such as the brain, liver, heart and skin. The three major forms of 
estrogens in women are estrone (E1), 17β-estradiol (E2) and estriol (E3). The 
most potent and prevalent estrogen in premenopausal women is E2, which is 
produced within the ovary by thecal and granulosa cells. Aromatase is the 
enzyme necessary for the final step of E2 synthesis, and it is expressed in 
granulosa cells as well as in peripheral organs. During the menstrual cycle, 
E2 is highest right before ovulation, reaching 110-410 pg/ml. In 
perimenopause E2 levels fluctuate and then decrease to below 35 pg/ml in 
postmenopausal women [1, 2]. The average age at menopause is 48-52 in 
developed countries and reflects the exhaustion of functional follicles in the 
ovaries. The number of follicular oocytes is set before birth and declines with 
apoptotic events before and after puberty. When women reach 45-55 years of 
age the oocytes are exhausted leading to a cascade of events ending with 
neuroendocrine desynchronization, fluctuations in estrogens levels and 
ultimately menopause [2].  
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Following menopause, estrone is the prevalent circulating estrogen; 
estrone is synthetized from conversion of androstenedione in adipose tissue, 
neurons and astrocytes [3]. Analyses of post-menopausal women who 
underwent natural menopause determined that adipose tissue mass 
correlates with estrone levels, which had osteoprotective effects and 
increased bone mineral density as well as decreased colorectal cancer risk [4] 
[5]. However, high estrone levels in post menopausal women also have been 
found to correlate with increased ER-positive breast cancer [6]. Estrone has 
higher affinity for ERα than ERβ, however it was shown to induce coregulatory 
protein recruitment to ERβ more efficiently than ERα [7, 8]. The third 
physiological estrogen, estriol, is the weakest activator of ERs and is 
produced during pregnancy by the fetal liver and adrenal glands [9]. 
Interestingly, estriol has been found to decrease the symptoms of multiple 
sclerosis (MS), explaining the improvement of women with MS during 
pregnancy [10].   
NEUROPROTECTION OF ESTROGEN 
Learning and Memory 
 The study of the effects of estrogens on cognitive functions started in 
the 1950’s when a random controlled study on 75-year old women showed 
that 12 months of treatment with E2 improved their verbal intelligence quotient 
(IQ) while the IQ scores of the placebo treated women decreased over that 
same period of time [11].  Since then randomized observational and 
longitudinal studies have investigated the clinical effects of estrogens on 
cognitive functions, anxiety, mood, and memory using standard tests of 
neuropsychological function. Overall 71% of studies concluded a significant 
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beneficial effects of E2 [12]. However interpretation of these studies is 
complicated by several confounding variables such as age and dosage, tests 
used to evaluate cognition, and length of treatment. A more definitive 
understanding of the molecular effects of E2 is needed to help physicians 
better treat their patients. 
 Basic science studies have elucidated some of the mechanisms behind 
the neuroprotective effects of estrogens. In the 1990s, Catherine Woolley and 
Bruce McEwen found that E2 levels fluctuating across the estrous cycle 
correlate with synaptic changes in the hippocampus of female rats [13, 14].  
Indeed, higher E2 levels coincided with increased synaptic density, increased 
dendritic spines and arborization. In an in vivo study using ERβ-null mice, Liu 
showed that ERβ is required for the E2-enhanced hippocampal synaptic 
plasticity and hippocampal dependent cognition [15]. These and other studies 
have therefore linked E2 to synaptic plasticity changes in neuronal circuitry 
and architecture [16]. Moreover, behavioral experiments using female rats 
show that changes in their learning strategy vary with natural hormonal 
fluctuations, such as during the estrous cycle, strongly implying that 
hippocampal mediated learning and cognition was intrinsically linked with 
circulating levels of estrogens [17]. In an extensive behavioral analysis, Kiss 
et al. evaluated the effects of E2 treatment on cognition and depressive-like 
behaviors in young (3 mo), adult (7 mo) and middle-aged (12 mo) female rats 
[18]. Their results showed that E2 treatment improved spatial reference 
memory in all age groups and was beneficial for depressive-like behaviors in 
young and middle-aged rats.  Correlating with the behavioral data with 
neurochemical evaluations, hippocampal brain-derived neurotrophic factor 
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(BDNF) levels were increased by E2 treatment at all time points, while 
decreasing with age. BDNF mediates neuronal growth, survival, and plasticity 
in the nervous system. Several lines of evidence support an interaction 
between E2 and BDNF and their downstream neuroprotective, neurotrophic, 
and neuromodulatory effects [19]. Estrogens and BDNF have similar effects 
on the hippocampus and in the past years many studies have focused on the 
idea that BDNF is a mediator of estrogens’ effects. [20, 21]. By comparing the 
immunoreactivity of BDNF in the hippocampus during the estrous cycle, 
Sharfman showed that BDNF levels also cycle according to cycling estrogens 
[22].  
Pathogenic conditions 
Interestingly, studies suggest that E2 might prevent or delay the onset 
of Alzheimer’s disease (AD), the most common cause of dementia in women. 
In a 1998 meta-analysis Yaffe et al. concluded that treatment with estrogens 
decreased the risk of developing dementia in postmenopausal women by 29% 
and that several plausible biological mechanisms exist that could support 
estrogens’ use as a preventative and beneficial treatment of AD [23]. Case-
controlled clinical studies have been conducted since then, and a 2001 meta-
analysis concluded there is a 34% decreased risk of Alzheimer disease in 
women taking hormone treatment [24]. Research using animal models has 
also investigated a putative link between AD and E2 therapy. For instance, a 
recent study evaluated the use of a nonsteroidal selective androgen receptor 
agonist together with an ERβ agonist in a mouse model of AD, which resulted 
in improved cognition, reduced anxiety behaviors as well as an increase in 
Amyloid-β degrading enzymes [25]. The authors speculate that ERβ agonists 
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could be used as a potential therapy of patients with AD by interfering with the 
progression of the disease through degrading and clearing Amyloid β. In 
transgenic models of AD, different ERβ agonists led to prolonged survival, 
improved spatial recognition memory, cognition and lowered Amyloid-β 
accumulation [25, 26]. In the case of Parkinson’s disease (PD) and other 
neurodegenerative diseases, estrogens have been shown to protect the 
nigrostriatal dopaminergic pathway that is affected by these diseases [27, 28]. 
It is thought that both ERα and ERβ are necessary for this protection; 
however an animal model of PD showed that treatment with the ERβ agonist 
AC-186 prevented motor and cognitive deficits and mitigated neuronal loss in 
males but not in females [29, 30]. 
Other neuroprotective effects of estrogens have been attributed to 
ERβ. For example, several ERβ selective agonists have been shown to 
induce remyelination and repair in animal models of multiple sclerosis [31]. 
Inflammatory and neuropathic pains are also targets of ERβ regulation, as 
shown in vivo using the ERβ selective agent ERb-131 [32, 33]. Gliomas, 
aggressive brain tumors, are more common in males than females, indicating 
a possible beneficial effect of the higher levels of circulating estrogens in 
females; interestingly ERβ is highly expressed in male and female glioma 
cells, while ERα is not detected [34]. Indeed treatment with ERβ agonists 
DPN (Diarylpropionitrile) or liquitrigenin reduced proliferation in an in vitro 
glioma model and in vivo in mice that had a glioma xenograft [34].  
 Estrogens have also been shown to be neuroprotective in models of 
cerebral ischemia. Women overall have a lower incidence of stroke than men, 
but following menopause this difference decreases [35]. Studies have proven 
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that E2 exerts dramatic protection if administered either before or after the 
ischemic injury [36, 37]. For example, E2 treatment for seven days 
significantly reduced infarct size in a middle cerebral artery occlusion (MCAO) 
ischemic injury paradigm [37]. Moreover, a 2013 study showed periodic E2 
treatment increased neuronal survival following cerebral ischemia via bilateral 
carotid occlusion and systemic hypotension. [38] The study also 
demonstrated that learning and memory following ischemic damage was 
improved when the rats where administered an ERβ specific agonist, which 
might have been mediated by the ERβ dependent increase in CREB 
phosphorylation.  
Mood and affective disorders 
 The role of estrogen in anxiety and depressive disorders has been 
investigated both in clinical and basic science fields. Women experience 
increased depression, sleep disturbances, irritability, anxiety and panic 
disorders after menopause and ET has been show to improve mood, feelings 
of wellbeing and an overall increase in activity [39]. However, women in 
general report higher incidence of depression than men, yet animal models 
have shown both anxiogenic and anxiolytic actions of E2. These discrepant 
findings can be partly explained by differential actions mediated by the two 
estrogen receptor isoforms, ERα and ERβ. For instance, a 2005 paper by 
Lund et al., demonstrated that treatment with an ERβ specific agonist 
decreased anxiety-related behaviors in rats, whereas ERα specific agonists 
were anxiogenic [39]. Their findings suggest that the conflicting effects of 
estrogens might be due to inverse actions on anxiety behaviors by the two 
ERs. Indeed, studies have shown that ERα and ERβ have different signaling 
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pathways and downstream gene targets despite their equivalent binding 
affinity for E2 [40]. Overall, ERβ has beneficial effects on neurological 
diseases that have very different etiologies and in which different cell types 
are involved, highlighting its multifaceted functions.  
CARDIOPROTECTION OF ESTROGEN 
 The sex difference in the incidence of cardiovascular disease is well 
documented, women are less likely to develop heart disease than men, but 
this advantage is lost after menopause presumably due to significant 
reduction in circulating E2 [41-43].  
 Both estrogen receptor isoforms, ERα and ERβ, are widely expressed 
in cardiovascular tissue, in cardiac myocytes, fibroblasts, vascular smooth 
muscle cells and endothelial cells and can influence gene expression as well 
as have rapid non genomic effects [44]. ERβ deficient mice develop 
hypertension, vascular dysfunction, and abnormal heart morphology as they 
age and therefore have been used to reveal the role for this receptor isoform 
in mediating E2 effects in the cardiovascular system. A study from Dr. E. 
Murphy found that ERβ mediates functional recovery following 
ischemia/reperfusion injury possibly by its regulation of fatty acid metabolism 
genes important in ischemic injury [45]. 
The development of several SERMs (selective estrogen-receptor 
modulators) also contributed to the understanding of the importance of ERβ in 
the cardiovascular system. ERβ-specific agonists reduced arterial pressure in 
ovariectomized spontaneously hypertensive rats, increased cardiac output 
and left ventricular stroke volume [46]. The same study also showed that ERβ 
activation also improved vascular reactivity and increased ERβ expression in 
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the aortic ring, both in endothelial cells in the intima and vascular smooth 
muscle cells [46]. Overall the study showed that ERβ specific agonists 
attenuate hypertension, vascular resistance and cardiac hypertrophy in 
spontaneously hypertensive rats. The authors also speculated that these 
positive effects might be mediated by enhanced vascular Nitric Oxide (NO) 
generation both via genomic and non-genomic mechanisms. Indeed ER 
increases expression of enzymes responsible for NO synthesis as well as 
activating them, possibly by recruiting and activating kinases [47].  
ERβ is necessary for the observed gendered differences in the 
attenuation of the hypertrophic response to pressure overload and improved 
recovery from ischemia/reperfusion injury [48, 49]. Furthermore, in animal 
models of ischemia reperfusion injury, treatment with the ERβ specific agonist 
improves functional recovery and upregulates protective genes such as 
antiapoptotic proteins, heat shock proteins and cyclooxygenase 2 [50]. These 
and other studies led to the proposal by Kathryn Sandber and Hong Ji that 
ERβ could be the “Alpha-Dog” in estrogen receptor-mediated protection from 
hypertension [51]. 
 An additional factor to consider when studying the effects of estrogen 
in post menopause is the comorbidity of depression and cardiovascular 
disease (CD) which ranges from 20 to 40% according to different studies. 
Middle-aged women are particularly susceptible to higher mortality following 
myocardial infarction (MI) if they have depressive symptoms (50% greater 
risk) [52-54].  The interesting link between heart disease and depression was 
analyzed in the SADHART trial (Sertraline AntiDepressant Heart Attack Trial), 
which was aimed at evaluating the effectiveness of the selective serotonin 
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reuptake inhibitor (SSRI) Sertraline in treating major depression in patients 
with acute myocardial infarction (MI) or unstable angina. The trial concluded 
that Sertaline is safe and efficacious in depressed patients with ischemic heart 
disease, but could not detect differences in mortality between placebo and 
Sertaline treated patients because it was underpowered. It is also difficult to 
determine whether depression is a risk factor for coronary heart disease 
(CHD) or a cause of it. Kenneth E Freeland and Robert M Carney in a recent 
report supported the idea that depression predicts worse outcome in patients 
with CHD and possibly improving the depressive symptoms could determine 
better cardiovascular prognosis [55]. Not only is comorbidity of depression 
and CD increasingly prevalent in middle-aged patients, but also menopausal 
women are particularly susceptible to have both these conditions. The 
elevated risk of both depression and CD in menopausal women is well 
accepted but the reason for this or the possible improvement from using HT 
needs further investigation [53].   
 Overall, several studies confirm estrogen’s positive effects on the 
cardiovascular system and the importance of ERβ in mediating these 
responses, but how age and timing of ET influences cardioprotection needs 
further investigation.  
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Figure 1 Summary of studies depicting the specific cardioprotective and 
neuroprotective effects of ERβ.  
Cardioprotection
Positive effects of ERβ
Neuroprotection
Induce remyelination in MS
Prevent motor and cognitive 
deficits in PD
Improve neuronal survival
Reduce 
Neuropathic/inflammatory Pain
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Reduce ischemia/reperfusion 
injury
Induce vasodilation
Reduce ventricular hypertrophy
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Reduce coronary heart disease
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THE TIMING HYPOTHESIS 
 The constant theme in neuroprotection and cardioprotection of 
estrogens in clinical studies is the importance of the time of initiation of ET 
(estrogen therapy alone)  in women. The concepts referred to as “window of 
opportunity” or “timing hypothesis” emerged when analyzing several clinical 
studies and finding that the variety of results was due to the span of ages of 
the women enrolled in the studies. When analyzing data by grouping for the 
age of initiation of ET, it was clear that estrogens alone reduced risk of 
cognitive decline and dementia when administered to women in the early 
stage of menopause [56]. Postmenopausal women receiving ET in a 2012 
Danish study also had significantly reduced risk of mortality and heart failure, 
without an increased risk of breast cancer or stroke [57]. The WHI ET follow-
up showed that women 50-59 of age had statistically significant reduction in 
coronary heart disease (Hazard Ratio (HR) of 0.59), myocardial infarction (HR 
0.54) and overall mortality (0.73) [58]. These are only a few examples of how 
cognitive and cardiovascular health of menopausal women can be improved if 
ET is started at the right time (i.e. in early menopause).  
 Despite the well-established evidence for cardioprotective effects of 
E2, the large scale clinical trial designed to assess the health benefits of E2 in 
postmenopausal women – the WHI- was suspended because of an increased 
risk of stroke and coronary heart disease among the HT participants [59].  
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 Figure 2. The Timing Hypothesis. 
 
Unfortunately, most physicians stopped prescribing ET to their patients 
after the WHI prematurely interrupted its study in 2002 and published their 
early results that showed adverse effects and increased mortality. A recent 
analysis by Dr. Phillip Sarrel published in the American Journal of Public 
health made the news when the author stated that avoiding ET by women in 
2002-2011 caused the premature death of 50000 women [60]. He then 
emphasized the need to call attention to the beneficial effects of ET for 
women 50-59 which should prompt doctors to prescribe it to their patients in 
that age group. A better understanding of the contribution of age on the 
effects of estrogen on cognitive and cardiovascular health are needed to help 
guide physicians in providing the best care to their patients, and my project 
will shed light on the molecular mechanisms for this age-related shift in E2 
efficacy. 
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ESTROGEN RECEPTOR BETA 
 Estrogen receptors are nuclear steroid receptors widely expressed in 
both reproductive and non-reproductive tissues and act as transcription 
factors; therefore they play a central role in many life processes including 
normal physiology [61]. In 1996 a group led by Jan-Ake Gustavsson 
successfully cloned the second estrogen receptor, expressed in rat prostate 
and ovary, named ERβ [62]. Initially described as a 485 amino acid long 
protein, further studies revealed an upstream AUG start site, making rERβ 
530 amino acids long, with a calculated molecular weight (MW) of 59.152 KDa 
[63]. Subsequent studies identified several splice variants, the first and better 
characterized being ERβ2, first described in 1998 and widely expressed [64]. 
In the brain ERβ is expressed in several hypothalamic nuclei, hippocampus, 
cerebellum, olfactory bulb, amygdala, cortex, and spinal cord [65]. 
Peripherally it is expressed in the cardiovascular system (myocytes, 
endothelial cells, fibrocytes), ovary, prostate, skeletal system (osteoblasts, 
osteoclasts and osteocytes), gastrointestinal tract, pancreas, adipose tissue 
and liver [61].  
 
Figure. 3. Domains of ERβ.  
  
AF-1 DBD D AF-2-LBD F
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The structure of ERβ is that of a classical nuclear steroid receptor 
organized in domains each with a particular structure and specific functions 
(Fig.3). The N-terminal A and B domains are collectively defined as AF-1 
(Activation Function-1, or N-terminal transactivation domain), a highly variable 
domain amongst the steroid receptor family. Many residues in the AF-1 
domain are phosphorylated by various kinases; the AF-1 domain is also 
fundamental for binding to coregulatory proteins [63, 66]. The AF-1 domain is 
intrinsically disordered (ID) in solution, therefore its structure is difficult to 
analyze, but progress is being made in understanding its binding to 
coregulatory proteins that leads to modulation of its transcriptional regulation 
[67]. This domain is also thought to mediate the known ligand independent 
regulation of transcription by ERβ [68-70]. The C domain is the DNA-Binding 
Domain (DBD) involved in DNA recognition and binding. In the case of 
estrogen receptors the DBD recognizes Estrogen Responsive Elements 
(EREs), in the promoter of target genes. The DBD is partially conserved with 
ERα, which can also recognize and bind to ERE sequences. The ERE is an 
inverted palindromic DNA consensus sequence (5’ GGTCAnnnTGACC 3’) 
that the DBD has a high affinity for [71]. The D domain of ERβ is the hinge 
domain, a flexible domain allowing for the conformational changes of the 
receptor. The E domain is the Ligand Binding Domain (LBD) or AF-2, which is 
responsible for ligand binding of both agonists and antagonists, dimerization, 
interactions with coregulatory proteins and conformational changes caused by 
ligand binding [72]. The precise function of the small C-terminal F domain of 
ERβ has not been identified yet, although it has been proposed to influence 
ligand binding and coactivator binding [73]. 
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 According to the classic model of steroid receptor functioning, ERβ is 
normally present in the cytoplasm bound to chaperone proteins. Following 
ligand binding it dimerizes and translocates to the nucleus, where it binds to 
the ERE and, together with coregulatory proteins, activates gene transcription 
(Fig. 4). Steroid receptors are therefore highly dynamic, being shuttled to and 
from the nucleus and in proximity of the cell membrane or cellular organelles.  
  
Figure 4. Classical model of ERβ’s action. 
  
E2
E2
E2 E2
RNA Pol
Coregulators
Hsp90
Transcription 
Factors
Regulation of 
Transcription
 
 
18 
 
The ERα and ERβ isoforms can often be co-expressed in a tissue and form 
homo or heterodimers. It was shown in 1997 that ERα and β can form 
heterodimers on the DNA at ERE sequences and are capable of binding to 
coregulatory proteins and activating transcription [74]. However the 
heterodimer is potentially functionally distinct from the homodimer, giving ERs 
a wider possibility of gene regulation. The characteristics of the heterodimer 
were analyzed in vitro in a 2004 paper by Li et al. showing that heterodimer 
binding to E2 and activation of ERE were similar to the α-α homodimer [75]. 
However ERβ is known to act as a dominant inhibitor of ERα, and it was 
initially thought that the function of ERβ was to modulate ERα transcriptional 
activity [76]. This adds to the complexity of estrogens' signaling and 
determines the variety of effects estrogens can have in vivo in different 
tissues that display different expression of ERα and ERβ. 
PHOSPHORYLATION OF ERβ 
 Post translational modifications (PTMs) such as phosphorylation, 
ubiquitination, acetylation and sumoylation have been identified for several 
steroid receptors, including ERs. These modifications can potentially alter 
each step of ERs function from ligand binding, dimerization, protein:protein 
interactions, DNA binding and ultimately ER function [66, 77]. For example, 
the first evidence that ERs can have ligand independent function was 
attributed to phosphorylation of the receptor after epidermal growth factor 
(EGF) treatment [78]. Furthermore EGF treatment to ovariectomized rats 
mimicked the effects of estrogens, as it leads to proliferation in the uterus [79] 
. We now know that extracellular factors such as EGF can initiate the 
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signaling cascade leading to kinase activation and ER phosphorylation and 
activation.  
Although consensus sites for several kinases are present in ERβ, only 
a few have been described and confirmed as actual phosphorylation sites 
[66]. The experimentally confirmed phosphorylation sites for the human ERβ 
are S87 and S105 [80, 81]. Studies of the phosphorylation of the mouse 
isoform of ERβ have also shown phosphorylation at the homologous sites 
(S106 and S124) and other sites mostly in the N-terminal domain, which are 
less characterized [68]. 
Phosphorylation of ERβ has important functional implications. In a 
2012 paper by Lam et al. phosphorylation of S105 inhibited breast cancer cell 
invasion and migration in vitro [81]. Phosphorylated S105 is also highly 
prevalent in human samples of breast cancer tissue, where ERβ is known to 
be antiproliferative [81, 82]. Phosphorylation of hERβ at S87 and S105 
(mouse S106 S124) was shown to recruit the coregulatory protein steroid 
receptor coactivator-1 (SRC-1) in vitro and increase transcriptional activation 
at ERE in a ligand independent way [68]. The phosphorylation of ERβ has 
been shown to be mediated by two MAPKs, p38 and ERK, in in vitro kinase 
assays on the human and mouse ERβ form [68, 81].    
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Figure 5. ERβ phosphorylation sites. 
 
Overall phosphorylation of steroid receptors is pivotal for their 
functioning, and the little that is understood about the actual phosphorylation 
of ERβ and how these influence their functioning is mostly from in vitro studies 
using breast cancer cell models. More needs to be done to characterize the 
molecular functional consequences of phosphorylation and describe ERβ 
phosphorylation in non-cancerous tissues, such as the brain and heart where 
ERβ is known to have important functions. Furthermore, to my knowledge 
there are no reports describing the effects of age and E2 on ERβ 
phosphorylation. 
COREGULATORY PROTEINS 
 The recruitment of coregulatory proteins to steroid receptors is a 
fundamental step in their functioning. Coregulatory proteins can activate 
(coactivators) or repress (corepressors) gene transcription and are required 
for proper signaling of all steroid receptors. After binding to the steroid 
receptor they serve as scaffolds for the larger complex of proteins that form 
the pre-initiation complex on the promoter of the responsive gene. Most of the 
classic coregulatory proteins for ER belong to the SRC (Steroid Receptor 
Coregulator) family and were first identified in 1994 in the lab of Myles Brown 
as estrogen-receptor associated proteins necessary for ER functions [83]. 
Since then the functions of SRC proteins have been elucidated and their 
importance in cell physiology has grown. Coregulatory proteins were recently 
AF-1 DBD D LBD F
P P
S87 S105
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defined by Dr. Bert O’Malley as “masters of system biology” to emphasize 
their importance [84]. They are not mere bridges between ERβ and the 
transcriptional machinery but integrate signaling cascades by binding to 
multiple transcription factors, and their dysregulation can lead to serious 
consequences such as development of cancer [85].  The coactivators SRC1 
and SRC3 interact and positively regulate transcriptional regulation mediated 
by several steroid receptors, including ERβ. Corepressors, such as silencing 
mediator for retinoid and thyroid hormone receptor (SMRT) and nuclear 
receptor corepressor (NCoR), repress or silence steroid receptor mediated 
regulation of transcriptional activity [85].  
 To date, more than 350 steroid receptor coregulators have been 
reported. However the ER interactome comprises an impressive amount of 
proteins, not only classic coregulators but binding partners involved with cell 
functions ranging from apoptosis to cell structural proteins to metabolic 
proteins to RNA splicing. For example, over 743 proteins associate with ERβ 
in the ventral hippocampus and several of these interactions are age and 
estrogen dependent [86]. Other studies have shown that the interactome of 
ERs in breast cancers is made of hundreds of proteins [87, 88]. These newly 
discovered interacting partners are an insight to the potentials of ER signaling.  
MITOGEN ACTIVATED PROTEIN KINASES 
 Age and E2 modulate cell signaling pathways critical for regulating 
basic cellular processes. Mitogen Activated Protein Kinases (MAPKs) are a 
family of Serine-Threonine protein kinases that link extracellular signals to 
intracellular responses [89, 90]. They are highly complex and interesting as 
they regulate cell activities including proliferation, differentiation, apoptosis 
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and cell survival.  Nearly every physiological and pathological event studied 
involves MAPKs, which indicates not only their essentiality but also their 
complexity. The MAPK family includes p38 MAPK, extracellular signal-
regulated kinase (ERK) and c-Jun NH2-terminal kinase (JNK), however as 
only p38 and ERK kinases have been shown to target ERβ for 
phosphorylation we will focus our attention to those [68, 81]. 
MAPK family members were first discovered and sequenced in the 
1980s and 90s after their activation was observed following mitogens 
stimulation, hence their name [90].  These kinases are regulated themselves 
by phosphorylation at their Threonine-x-Tyrosine phosphorylation site motif. 
MAPKs activation is the last of a three step activation cascade from MAP3K to 
MAP2K to MAPK. Once phosphorylated (i.e. activated) they in turn 
phosphorylate substrate proteins at Serine or Threonine residues in specific 
recognition sequences [91].  While MAPKs phosphorylate S/T residues 
included in a conserved motif, this sequence is variable, allowing for substrate 
discrimination and a wider pool of targets [92]. The strongest requirement for 
phosphorylation common to p38 and ERK kinases is the presence of a Proline 
directly at the C- Terminus of the phosphorylation site. Another characteristic 
feature of MAPKs is the presence of docking sites in their substrates; the best 
characterized being D-sites and F-sites [93].  These mediate the interaction 
between sequence motifs in the target protein far from the phosphorylation 
sites and region of the kinase separate from the active site. Because of their 
heterogeneous preference for D- and F- sites, ERK and p38 interact with 
different target proteins, therefore having differential downstream effects. 
Furthermore docking sites assure specificity and selectivity of kinase 
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substrate interactions, reducing the number of potential substrates [93]. 
Interestingly 30% of human proteins have at least one MAPK phosphorylation 
site; however fewer have the docking sites necessary for the kinases to 
interact strongly and phosphorylate them.  
The knowledge of the activators, substrates and functions of MAPKs 
are ever expanding, however when they were first discovered they were 
deemed stress-activated protein kinases (SAPKs) because of their 
responsiveness to toxins, physical stresses and inflammatory cytokines [92, 
94]. Generally it can be said that ERK1/2 are preferentially activated in 
response to growth factors and extracellular stimuli while p38 is more 
responsive to stresses such as osmotic shock, ionizing radiation and 
cytokines [95]. MAPKs can be present in several cell compartments, such as 
the nucleus, cytoplasm, mitochondria and close to the cell membrane. Among 
their targets are other kinases and transcription factors allowing them to 
integrate signals and activate a variety of responses. While it can be difficult 
to dissect the effects of MAPKs activation from a specific stimulus, it is known 
that they can regulate mitosis, apoptosis, survival, differentiation, gene 
expression and more. MAPKs involvement in human disease has been 
proven and several kinases have been considered as targets of 
pharmaceutical modulation [96].  Of note, cancers such as melanoma and 
breast and ovarian tumors can be brought about by mutations in proteins 
either participating in the MAPKs pathways or direct targets [97]. Inflammatory 
related diseases such a COPD (chronic obstructive pulmonary disease), 
rheumatoid arthritis and systemic lupus also show MAPKs dysregulation. 
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Interestingly, neurodegenerative disease such as Alzheimer’s, 
Parkinson’s and ALS (Amyotrophic lateral sclerosis) are characterized by p38 
and ERK alterations. For example, it has been shown that in a model of 
Alzheimer’s disease the oxidative stress induced by Amyloid beta 
accumulation leads to p38 activation and tau protein phosphorylation [98].  
The cardiovascular system is also regulated by MAPKs and these have been 
considered as potential targets in cases of infarction, hypertrophy and heart 
failure [99, 100]. Pharmaceutical companies are investigating small molecule 
inhibitors or activators of MAPKs and several clinical studies are underway to 
investigate whether these could prevent, treat or decrease the symptoms of 
the diseases they are involved in.  
In mammals, four splice variants of p38 kinase exist: p38α, p38β, p38γ 
and p38δ [101]. P38α was first isolated as a 38 KDa protein that was rapidly 
phosphorylated in a characteristic Thr-Gly-Tyr (TGY) motif following 
application of pro inflammatory stimuli  [102-105].  The four splice variant 
proteins have a 60% identity in sequence, but can be differentially activated 
by upstream kinases and have different target proteins. P38α and p38β are 
widely expressed, while p38γ and p38δ are only expressed in certain cell 
types. Because of the sequence similarity of the different p38 isoforms, it is 
difficult to separately investigate the functioning of each. The perfect 
homology in the TGY motif results in the impossibility to raise antibodies for 
only one of the active isoforms. Therefore phosphop38 antibodies will bind to 
all p38 isoforms. Further complicating the study of each isoform, small 
molecule inhibitors also do not discriminate between isoforms.  
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 The extracellular signal regulated kinase subfamily is comprised of the 
evolutionarily conserved ERK1 and ERK2 which have 83% amino acid identity 
[95]. Similarly to the p38 isoforms, ERK1 and ERK2 have perfect homology in 
their activating phosphorylation motif, resulting in antibodies that bind to both 
active forms. 
To our interest p38 has been found to be regulated by aging and 
estrogen treatment in different cell and animal settings. In a 2011 study, Li et 
al. hypothesized that p38, a key regulator of pro-inflammatory cytokine 
biosynthesis, would be activated by the low grade inflammation that is 
associated with the aging process [106]. By measuring cytokines and markers 
of inflammation in the lungs of young (2mo) and old (20mo) C57BL/6J mice 
they showed a significant increase of inflammatory markers with age [106]. 
They also measured p38 activation in the lung and whole brain homogenate, 
showing the activation of p38 was doubled in the older mice, confirming their 
initial hypothesis [106]. Furthermore, Yousin Suh measured age specific 
changes in MAPKs expression and activity in the brain and liver of 2 mo and 
26 mo female Fisher344 rats [107]. Again, p38 expression and activity was 
increased by 2.5 fold in the aged brain while no change in expression was 
measured in the liver [107]. In a separate study, the adrenal gland of 24-27 
mo rats had increased levels of active p38 compared to younger animals 
[108]. In contrast to that, age dependent inhibition of p38 activity was detected 
in the cortex of 24 mo rats compared to 6 and 12 mo animals [109]. MAPKs 
can be activated by extracellular stimuli and E2 has been shown to activate 
p38 and ERK in a rapid, non-genomic way in isolated cardiomyocytes as well 
as in neuronal cells [110] [111].   
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P38 has also been shown to have a role in reproductive physiology, 
and it is more highly activated in the granulosa cells of older patients [112]. 
The same study also examined cellular localization of p38 and found that 
activated p38 was more highly present in the nucleus of younger cells, while it 
mostly resided in the cytoplasm in granulosa cells of older patients [113]. The 
authors concluded that oxidative stress might be the cause for the different 
subcellular localization of p38, since reactive oxidative species (ROS) are 
known to induce translocation of p38 to the cytoplasm and are abundant in 
aged cells. In the cardiovascular system, activated p38 has been implicated in 
a wide spectrum of pathologies, such as hypertrophy, infarction, and systolic 
and diastolic heart failure [100, 114-116]. The signaling pathways that p38 
regulates could be linked to its role in heart pathology including apoptosis, 
pro-inflammatory gene regulation, myofilament modulation and remodeling of 
matrix proteins [115]. Several clinical trials involving p38 inhibitors have not 
yielded the positive results expected in regards to cardiovascular diseases, 
however there have been more encouraging results in rheumatoid arthritis 
treatment [100]. 
  Overall it is well understood that MAPKs signaling plays an integral 
role in aging, and their aberrant regulation might be involved in age-related 
disorders. The molecular mechanisms by which p38 activation can be 
detrimental are not well understood, but we can infer from the literature that 
the age-dependent activation of MAPKs might be at least part of the cause for 
cardiovascular disease in post-menopausal women.  
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Figure 6. ERK and p38 signaling.  
 
 
 
 
 
 
 
 
  
 
 
28 
 
EXPERIMENTAL DESIGN 
ANIMAL PARADIGM 
The Timing Hypothesis originated from clinical data and clearly points 
to time after onset of menopause as an important factor in HT success. 
Therefore, we designed an animal paradigm that allows us to discern the 
relative contributions of age, length of E2 deprivation and subsequent E2 
replacement over molecular and physiological responses (Fig. 7). The 
literature on animal models of menopause indicates that rats are the most 
appropriate non-primate animal model for menopause [117]. However, unlike 
primates, aging rats do not undergo a rapid decline in E2 levels so bilateral 
ovariectomy (OVX) is necessary to abolish endogenous E2, thereby ensuring 
an equivalent hormonal milieu. Our preliminary data show that a 
subcutaneous injection of 2.5 µg/kg E2 in aged (18mo) Fisher344 rats 
achieves circulating E2 levels of 50.56+/- 8.78 pg/ml, which is within the 
physiological range for post-menopausal patients receiving HT (17-75pg/ml; 
[118, 119]). Importantly, this paradigm will allow us to draw conclusions on the 
effects of duration of E2 deprivation prior to HT. Fisher344 rats (18mo; N = 
10/group, total = 90) will be administered E2 or safflower oil (vehicle) 
once/day x 3 days at 1 week, 4 weeks, 8 weeks or 12 weeks after OVX, 
reflecting women who begin HT closer to menopause versus those who 
waited for longer periods of time. 
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Figure 7. Animal Paradigm. 
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HYPOTHESIS AND QUESTIONS 
 Estrogens are neuroprotective and cardioprotective for women, however 
when administered long after menopause, they fail to improve their health. 
This age related switch in estrogens’ effects after prolonged deprivation has 
not been explained. It is possible that the estrogen receptors (ER) that 
mediate the protective effects are modified following menopause and no 
longer function as in the past. Phosphorylation is the most common protein 
modification and it can fundamentally alter a protein’s activity. The ERβ 
isoform of the receptor is highly expressed in the brain and heart and has 
been shown to mediate protective neurological and cardiovascular effects. 
Little is known about ERβ phosphorylation, but the Mitogen Activated Protein 
Kinases can in vitro phosphorylate ERβ in its N-terminal domain. This part of 
the protein mediates its interactions with coregulatory proteins that dictate its 
function as a transcription factor. The MAPKs responsible for this modification 
respond to cellular and extracellular stresses, which can increase with aging 
and disease and have been shown to be sensitive to estrogens. Therefore, I 
hypothesized that Mitogen Activated Protein Kinases are sensitive to age 
and prolonged estrogen deprivation leading to a differential 
phosphorylation of ERβ which results in altered transcriptional 
regulation. 
These are the questions I sought to answer: 
1. Is phosphorylated ERβ present in vivo in the brain and heart? (see 
Chapter III) 
2.  Does site specific phosphorylation of ERβ alter its activity as a 
transcription factor? (see Chapter III) 
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3. Does phosphorylation of ERβ alter its ability to bind to DNA? (see 
Chapter III) 
4. Is the activity of the MAPKs ERK and p38 sensitive to prolonged 
estrogen deprivation and estrogen treatment? (see Chapter IV) 
5. Is the expression of ERK and p38 dependent on prolonged estrogen 
deprivation and estrogen treatment? (see Chapter IV) 
6. Which ER mediates the effects of estrogen on MAPKs activation? (see 
Chapter IV) 
7. Can phosphorylated ERβ be detected and quantified in vivo? (see 
Chapter V) 
  32 
 
CHAPTER III 
PHOSPHORYLATION ALTERS ESTROGEN RECEPTOR Β-MEDIATED 
TRANSCRIPTION IN NEURONS 
Journal of Neuroendocrinology, 2015 Dec;27(12):861-71 
INTRODUCTION 
Nuclear steroid receptors are master regulators of a broad range of 
physiological processes through their actions as ligand-activated transcription 
factors. Estrogen receptors (ERα and ERβ) are members of this receptor 
superfamily and their cognate endogenous ligand is 17β-estradiol (E2), which 
is the major circulating form of estrogen in premenopausal women. ERα and 
ERβ are widely expressed in a variety of tissues, although ERα is particularly 
abundant in breast, uterus and ovary, due to its primary role in mediating the 
reproductive-related effects of estrogens. By contrast, ERβ is highly 
expressed in many non-reproductive tissues such as nervous, cardiovascular, 
skeletal, gastric, and adipose tissues, and has been implicated in mediating 
estrogens effects on anxiety, mood, and memory, as well as numerous other 
physiological processes  [15, 16, 40, 65, 120, 121]. Our basic understanding 
of ERα structure, function, and signaling pathways has significantly advanced 
in recent years, however similar aspects of ERβ function, especially in non-
reproductive tissue/cell types, remain unclear.
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The overall goal of these studies was to define the functional 
consequences of post-translational modifications to ERβ, namely site-specific 
phosphorylation, on its ability to transcriptionally activate gene promoter 
activity in neuronal cells.   
Post-translational modifications (PTMs) such as phosphorylation, 
ubiquitination, acetylation, and sumoylation have been identified for several 
nuclear steroid receptors, including ERs [122-126]. These modifications have 
the potential to alter all aspects of ER function including ligand binding, 
dimerization, protein:protein interactions, DNA binding and, ultimately, alter 
ER-mediated transcription. Although several kinase consensus sites have 
been predicted for ERβ, only a few have been experimentally confirmed [66]. 
Specifically, the serine residues S87 and S105 located in the N-terminal 
domain of ERβ are highly conserved among the mouse, rat, and human, 
suggesting that ERβ phosphorylation at these sites could be a common 
regulatory mechanism across species [81]. The N-terminal domain of ERβ 
exhibits greater than 80% homology across species and the specific amino 
acid residues flanking S87 and S105 are highly conserved [127]. By contrast, 
the N-terminal domain of ERβ has relatively low homology with ERα, which 
could contribute to the divergent actions of the two receptors. These S87 and 
S105 sites are targets of MAPKs (Mitogen Activated Protein Kinases) and the 
specific MAPKs, P38 and ERK, have been shown to phosphorylate human 
and mouse ERβ in vitro [81, 128]. Functionally, phosphorylation of these sites 
increased recruitment of the coregulatory protein SRC-1 (steroid receptor 
coactivator-1), while coincidentally increasing transcriptional activation at an 
estrogen response element (ERE) [128].  
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Phosphorylation of ERβ has been studied primarily in vitro using breast 
tumor cell models. The only reports of detection of phosphorylation of ERβ in 
vivo come from immunohistochemistry analysis of human breast cancer tissue 
using a human-specific antibody generated against the phosphorylated S105 
ERβ [81]. However, ERβ is highly expressed in non reproductive tissue such 
as the brain and heart, and its phosphorylation would have important 
functional consequences on those systems. Therefore, my first goal in these 
studies was to determine whether ERβ is phosphorylated in vivo in the brain 
as well as in the heart of female rats. Using PhosTagTM Acrylamide I was able 
to detect several phosphorylated species of ERβ in the dorsal hippocampus 
and left ventricle of the heart of aged (18 mo. Old) female rats. This, to my 
knowledge, is the first report of phosphorylated ERβ detection outside of the 
breast in any species.  
Previous work by my laboratory showed that p38 kinase inhibition 
altered ERβ-dependent activation of ERE and AP-1 (activator protein-1) 
promoter activity in neurons [70]. However p38 kinase inhibitors are broad-
spectrum inhibitors and can affect multiple signaling pathways in the cell, 
thereby making it unclear whether ERβ was a direct target of phosphorylation 
by p38 in those studies. Furthermore ERβ phosphorylation states were not 
determined. Therefore, in these studies I created phospho-mutants of ERβ to 
directly assess the consequences of ERβ phosphorylation on its 
transcriptional activity in neuronal cells.  I hypothesized that phosphorylation 
of ERβ at specific sites, S87 and S105, would alter ERβ mediated gene 
regulation in neuronal cells, both directly at a canonical ERE site and also 
indirectly through protein:protein interactions at an AP-1 site. I also tested 
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whether phosphorylation of S87 and S105 altered the binding affinity of ERβ 
to a canonical ERE sequence. Collectively, my results demonstrate that 
phosphorylation of S87 and S105 altered both estrogen-independent and 
estrogen-dependent ERβ mediated transcriptional regulation at ERE and AP-
1 sites in neuronal cells, but did not alter the DNA binding affinity to ERE 
sequences. Taken together, these data suggest that altered kinase activity in 
the brain, as occurs during aging, has the potential to alter the downstream 
expression of ERβ gene targets resulting in fundamental changes in brain 
function. 
RESULTS 
PHOSPHORYLATED SPECIES OF ERΒ ARE PRESENT IN THE DORSAL 
HIPPOCAMPUS OF AGED FEMALE RATS. 
The detection of phosphorylated ERβ in the brain and heart in vivo has 
not been previously demonstrated, likely due to its relatively low expression 
and the lack of commercially available phospho-specific antibodies targeting 
rERβ. A powerful tool that has recently emerged is PhosTagTM, a phosphate-
binding tag that slows the migration of phosphorylated protein during the 
electrophoretic run on polyacrylamide gels  [129]. Use of PhosTagTM 
acrylamide results in the detection of several bands when analyzed by 
Western Blot using specific antibodies for the protein of interest, and each 
band represents the target protein with a different degree of phosphorylation. 
For instance, higher bands indicate that the target protein contains several 
phosphate groups, which result in a slower migration through the gel and is 
visualized as a higher band shift. To verify the specificity of the 
phosphorylated bands detected, protein samples can be treated with alkaline 
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phosphatase (AP), which will dephosphorylate the protein and result in the 
absence of detectable phosphorylated bands on the Western blot. The only 
band detected will be a lower band representing the non-phosphorylated 
protein of interest.   
I tested whether phosphorylated ERβ is present in the dorsal 
hippocampus and left ventricle of aged female rats to provide rationale for 
assessing the functional consequences of phosphorylated ERβ in neuronal 
cells. Estradiol (E2) is known to have direct effects on the dorsal 
hippocampus, a brain region involved in cognition and memory formation and 
a region where ERβ is more highly expressed than ERα [130, 131]. Because 
E2 therapy is often prescribed to ameliorate the negative cognitive and 
cardiovascular issues that accompany menopause, I used a model of 
surgically-induced menopause followed by acute E2 treatment to test whether 
1) phosphorylated ERβ is present in the brain and heart, and 2) E2 treatment 
alters ERβ phosphorylation levels in the brain. Aged Fisher 344 rats (18 mo. 
Old) underwent ovariectomy (OVX) followed by acute E2 or vehicle 
administration for 3 days (see Methods).  
Fig. 8 shows a representative PhosTagTM SDS-PAGE blot probed for 
ERβ with the ERβ specific antibody. Phosphorylated ERβ was detected in the 
dorsal hippocampus of both the vehicle and E2-treated animals (Fig. 8A, 
arrow). Following AP treatment this same band disappeared, indicating that 
the band that shifted was specific for phosphorylated ERβ.  AP treatment did 
not diminish the intensity of the lower band, which represents 
unphosphorylated ERβ, however the higher band is very dark indicating that a 
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large amount of ERβ in the aged female dorsal hippocampus was 
phosphorylated to some degree (Fig. 8A).  
 In Fig.8B phosphorylated ERβ is detected in the left ventricle of aged 
female rats. Conversely to the dorsal hippocampus, more than one band is 
absent following AP treatment. This could have different explanation. First, it 
is possible that an increasing amount of phosphates are bound to ERβ. This 
would result in the several bands detected: the higher being ERβ with several 
phosphates attached which would cause a slower electrophoretic run in the 
PhosTagTM gel. The other possible explanation is that splice variants of ERβ 
are present in the heart, and that those are also phosphorylated.  ERβ2 is a 
widely expressed splice variant which has as an additional 18 amino acid 
insertion far from the antibody binding site, therefore it could recognize and 
bind it as well [132-134]. ERβ2 protein has not been detected in the heart but 
its mRNA has been detected in the cardiovascular system [134]. I hypothesize 
that the lower band in the AP treated samples is ERβ1, the band above ERβ2 
and bands that are only present in absence of AP treatment a combination of 
phosphorylated species of ERβ1 and ERβ2.  
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A) 
 
 
 
 
 
B) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8.  Expression of phosphorylated ERβ in the dorsal hippocampus 
of aged female rats. Protein isolated from the dorsal hippocampus (50 μg) 
was resolved using Phos-Tag TM SDS-PAGE electrophoresis and probed for 
ERβ with the ERβ specific antibody (SC-150). Phos-TagTM binds phosphate 
groups and increased protein phosphorylation retards gel migration. Alkaline 
phosphatase (AP) treatment removes phosphate groups allowing the protein 
to migrate further through gel.  Aliquots of the same dorsal hippocampus 
protein sample were treated with different amounts of AP. Arrow indicates 
phosphorylated ERβ. Samples not treated with AP show upper band, 
indicating presence of phosphorylated ERβ that is abrogated in samples 
treated with either 30 or 60 units of AP.  
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ERβ PHOSPHORYLATION ALTERS LIGAND DEPENDENT AND LIGAND 
INDEPENDENT ACTIVATION OF ERE-MEDIATED TRANSCRIPTION IN 
NEURONAL CELLS. 
 To study the functional effects of phosphorylation of ERβ in neurons, I 
used site-directed mutagenesis to mutate S87 and S105 into alanine (A), a 
residue that cannot be phosphorylated, or glutamic acid I, a residue that 
resembles a phosphorylated serine because of its similar negative charge and 
molecular bulk [135]. The expression vector constructs used in the transient 
transfection analysis are listed in Table 1. ERβ acts as a transcription factor in 
cis by directly binding to DNA at consensus ERE sequences and activating 
downstream gene transcription. To test whether phosphorylation of ERβ alters 
its ability to regulate ERE-mediated transcription, I transiently co-transfected 
wild type (WT)-ERβ or one of the mutants listed in Table 1 with the reporter 
construct ERE-tk-luc in a hippocampal-derived cell line (HT-22).  
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Table 1. List of ERβ expression vectors. 
  
Vector name Characteristics
ERβ Wild type ERβ Wild type
87E Phospho mimetic at S87
87A Phospho null at S87
105E Phospho mimetic at S105
105A Phospho null at S105
AA Phospho null at S87 and S105
EE Phospho mimetic at S87 and S105
AE Phospho null at S87, phospho mimetic at S105
EA Phospho mimetic at S87, phospho null at S105
Phospho 
mutants
Double 
mutants
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First I analyzed the ERE-mediated promoter activity for each of the 
phospho-mutants with a single site mutated. A two-factor ANOVA analysis 
revealed that there was a statistically significant interaction between plasmid 
and treatment, demonstrating that the effect of E2 on ERE-mediated promoter 
activity depends on whether ERβ is phosphorylated at serine 87 and/or 105 
(Fig. 9A; F (5,74)= 9.790, p<0.001). Consistent with previous studies, WT-
ERβ tended to increase ERE-dependent transcription in the absence of ligand 
(an approximate 2 fold  increase) and E2 treatment increased it to a much 
greater statistically significant extent (an approximate 5.5 fold increase, Fig. 
2A) [136]. I then analyzed the ERE-mediated promoter activity for each of the 
phospho-mutant receptors. Mutation of ERβ at serine 87 had differential 
effects on ERE-mediated promoter activity depending on whether it was 
phospho-null or phospho-mimetic.  First, mutation to alanine (87A, phospho-
null) increased ERE-mediated promoter activity to a similar extent as WT-ERβ 
in the absence of E2, whereas E2 treatment significantly increased ERE-
mediated activity to a greater extent. These results suggest that 
phosphorylation at this site hinders the E2-dependent activation of the 
receptor. Interestingly, the opposite effect was observed for mutations at the 
serine 105 site. In that case, the phospho-null mutation (105A) was not 
different from WT-ERβ. By stark contrast, the phospho-mimetic (105E) 
increased not only the E2-independent (by approximately 4 fold), but also the 
E2-dependent, activation of ERβ.  
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 Figure 9. Effects of ERβ phosphorylation on ERβ-mediated promoter activity 
at an ERE site. Hippocampal-derived (HT-22) cell lines were transiently co-
transfected with an ERE-tk-Luciferase reporter construct and the wild type 
ERβ or (A) single phospho-mutant ERβ expression vector (S87A, S87E, 
S105A, S105E) or (B) double phospho-mutant ERβ expression vector 
(S87A+S105A; S87E+S105E; S87A+S105E, S87E+S105A) (B). Cells were 
treated with 100 nM E2 or vehicle (0.01% ethanol) for 15 hours. Data are 
expressed as the mean percent change compared to empty vector control ± 
SEM. Different letters denote statistically significant differences as calculated 
with two-way ANOVA and Tukey post-hoc analysis (p<0.05). 
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 The previous experiments demonstrated the effects of a single amino 
acid manipulation on ERE- and AP-1-mediated transcription. In those 
experiments, the phosphorylation status of the opposing site was unknown 
and entirely dependent on the endogenous kinase activity in the cell. 
Therefore, in this next series of experiments I tested whether simultaneous 
phosphorylation (i.e. S87E + S105E (EE)) or complete absence of 
phosphorylation (i.e. S87A and S105A (AA)) at both serine residues could 
further alter ERβ regulation. In addition, I also tested the effects on ERE-
mediated transcription when one site was phosphorylated, but not the other 
(i.e. S87A + S105E (AE); S87E + S105A (EA)). Each of the double mutant 
vectors (see table 1) were transiently co-transfected with an ERE-tk-luc 
reporter construct in HT-22 cells as described before.  
A two-factor ANOVA analysis revealed a statistically significant 
interaction between plasmid and treatment, once again indicating that E2 
regulation of promoter activity depends on the phosphorylation status of both 
ERβ S87 and S105 residues (Fig. 9, F( 5,78)= 5.271, p< 0.001). Figure 9B 
demonstrates the effects of the double mutants on ERE-mediated promoter 
activity. All of the double mutants increased ERE-mediated transcription in the 
presence of E2, although the increase was greater when the two serine 
residues had an opposite phosphorylation status (AE, EA, Fig. 9B). Moreover, 
the AE mutation increased ERE-mediated activity by more than 2 fold in the 
absence of ligand.  
Overall, these data demonstrate that phosphorylation of ERβ at both 
S87 and S105 has important functional consequences on its ability to 
transcriptionally activate ERE-mediated promoters in neurons. 
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ERβ PHOSPHORYLATION ALTERS LIGAND DEPENDENT AND LIGAND 
INDEPENDENT ACTIVATION OF AP-1 DEPENDENT TRANSCRIPTION IN 
NEURONAL CELLS. 
Estrogen receptor β can also act as a transcription factor in trans by 
tethering other transcription factors, thereby regulating a larger subset of 
genes whose promoters might lack a consensus ERE. For instance, ERβ-
mediated regulation at AP-1 sites requires ERβ interaction with transcription 
factors of the Fos and Jun families. Similar to my observed results on ERE-
mediated promoter activity, a two-factor ANOVA analysis revealed that there 
was a statistically significant interaction between plasmid and treatment (Fig. 
10A; F (5, 59)= 6.046, p< 0.001). First, WT-ERβ had a constitutive (ligand 
independent) inhibition of AP-1-mediated promoter activity (an approximate 
50% decrease, Fig. 10A), which showed a trend towards a decrease following 
E2 treatment. These results are consistent with my previous reports of ERβ 
repression of AP-1-mediated promoter activity in neuronal cells [70, 136]. 
Surprisingly, however, mutation of S87 or S105 to any form (phospho-null or 
phospho-mimetic) completely abolished the ligand independent inhibition of 
AP-1-mediated transcriptional regulation, yet the E2-induced reduction was 
preserved. These results suggest that S87 and S105 are critical residues 
mediating the ligand independent actions of ERβ at an AP-1 site.  
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Figure 10. Effects of ERβ phosphorylation on ERβ-mediated promoter 
activity at an AP-1 site. Hippocampal-derived (HT-22) cell lines were 
transiently co-transfected with an AP-1-tk-Luciferase reporter construct and 
the wild type ERβ or (A) single phospho-mutant ERβ expression vector 
(S87A, S87E, S105A, S105E) or (B) double phospho-mutant ERβ expression 
vector (S87A+S105A; S87E+S105E; S87A+S105E, S87E+S105A) (B). Cells 
were treated with 100 nM E2 or vehicle (0.01% ethanol) for 15 hours. Data 
are expressed as the mean percent change compared to empty vector control 
± SEM. Different letters denote statistically significant differences as 
calculated with two-way ANOVA and Tukey post-hoc analysis (p<0.05). 
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 I next tested whether simultaneous phosphorylation (i.e. S87E + S105E 
(EE)) or complete absence of phosphorylation (i.e. S87A and S105A (AA)) at 
both serine residues could further alter ERβ regulation at an AP-1 site. The 
regulation of AP-1-mediated transcription by double ERβ mutants is shown in 
Figure 10B. Surprisingly, the ligand independent inhibition of AP-1 was 
restored when both S87 and S105 were concurrently mutated, while the 
single mutation of those same sites abolished the constitutive inhibition of AP-
1 regulation by WT-ERβ (Fig. 10B).  Moreover, E2 significantly inhibited the 
constitutive repression to a greater extent when S105 was mutated to a 
phospho-mimetic I regardless of the phosphorylation status of S87 (Fig. 10B; 
F (5,70)= 3.741, p< 0.005).  
Overall, I show that ERβ regulation of AP-1 dependent transcription is 
fundamentally altered by single, but not double, mutation of S87 and S105.  
PHOSPHORYLATION OF ERΒ ALTERS TAMOXIFEN EFFECTS ON ERE 
AND AP-1 TRANSCRIPTION IN NEURONAL CELLS. 
Next, I tested whether phosphorylation of ERβ alters the effects of 
tamoxifen (TAM), a known selective ER modulator (SERM). TAM can be both 
agonistic and antagonistic, depending on cell type, ER subtype, and promoter 
response element [137-141]. I have previously shown than TAM abrogates 
the constitutive activation of ERE in HT-22 neuronal cells, and this was also 
true for some of the phospho-mutants tested (Fig. 11) [136]. Similar to the 
previously described experimental results, a two-factor ANOVA revealed a 
significant interaction between the two factors, plasmid type and TAM 
treatment (F (5, 71) = 12.978, p< 0.001). Specifically, TAM treatment 
completely eliminated the constitutive ligand-independent activation (i.e. 
 
 
 
 
47 
vehicle-treated) of ERE-mediated transcription (Fig. 11A). Further, 
phosphorylation of S105 (105E) increased constitutive activity to the greatest 
extent (>400%), and also increased TAM dependent activation of ERE-
mediated transcription compared to wild type ERβ (Fig. 11A). These results 
suggest that phosphorylation of S105 would alter transcription of ERE 
regulated genes following TAM treatment.  
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Figure 11. Effects of tamoxifen treatment on ERβ or ERβ mutant-mediated 
promoter activity at an ERE or AP-1 site. Hippocampal-derived (HT-22) cell 
lines were transiently co-transfected with an (A) ERE-tk-Luciferase or (B) AP-
1-tk-Luciferase reporter construct and the wild type ERβ or phospho-mutant 
ERβ expression vector (S87A, S87E, S105A, S105E). 24 hours following 
transfection, cells were treated with 100 nM 4-OH-tamoxifen (TAM) or vehicle 
(0.01% ethanol) for 15 hours. Transfection efficiency was normalized using a 
second renilla luciferase reporter construct (rLUC) in all experiments. Data are 
expressed as the mean percent change in fLUC/rLUC compared to empty 
vector control ± SEM taken from 4 independent experiments with 6 
replicates/experiment. Different letters denote statistically significant 
differences as calculated with two-way ANOVA and Tukey post-hoc analysis 
(p<0.05). 
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Our previous studies showed that TAM abolished the observed ligand 
independent inhibition of AP-1 activity by ERβ. The current studies confirm 
that TAM does abolish the ligand independent inhibition of AP-1 activity for 
the WT-ERβ (Fig. 11B). However, mutation of S87 or S105 alone abolished 
the ligand independent repression of AP-1-mediated transcription (see Figs. 
10, 11B vehicle), and treatment with TAM did not have any additional effects.  
Phosphorylation of ERβ does not alter binding to an ERE sequence 
Phosphorylation of nuclear receptors has previously been shown to 
alter their binding affinity for consensus response elements, such as an ERE, 
in the promoter regions of their target genes. Moreover, I have previously 
shown that WT-ERβ can bind to consensus ERE sequences both in the 
absence and presence of E2, but the effects of phosphorylation of S87 or 
S105 have never been investigated [70, 136]. Therefore, I tested whether 
phosphorylation of ERβ at S87 or S105 altered its ability to bind to consensus 
ERE sequences using electromobility shift assays. After autoradiography, I 
observed that all receptor proteins produced an equally strong shift in the 
position of the 32P-labeled ERE oligonucleotide, demonstrating that 
phosphorylation of S87 and S105 did not affect ERβ:DNA binding to that 
consensus sequence (Fig. 12). 
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Figure 12 Effects of S87 and S105 phospho-mutation on DNA binding to a 
consensus ERE sequence. Vitellogenin ERE consensus sequence was 32P-
end labeled and incubated with in vitro translated wild type or phospho-mutant 
ERβ protein receptor lysates. Receptor lysates were incubated with 100 nM 
E2 or vehicle for 16 hr. prior to 30 min. incubation with 32P-labled ERE 
oligonucleotide and resolved on a 6% retardation gel. Gels were dried and 
exposed to a phosphoImager screen for 4 hours prior to imaging. Specific 
binding was confirmed by incubating with a scramble radiolabeled DNA 
sequence (lane 2) or by addition of a 1000X unlabeled ERE oligonucleotide 
prior to addition of radiolabeled vitellogenin ERE (lane 3). (Neg: negative 
control, no lysate). Relative densitometry of gel bands taken from six 
independent experiments were quantified using IMAGE J (NIH, Bethesda, 
MD, USA). The data are reported as the mean ± SEM density of pixels. Two-
way ANOVA analysis indicated no statistically significant differences.  
 
  
Treatment
Receptor ERβ 87A 87E 105A 105E ERβ 87A 87E 105A 105E
Band Intensity (+/- SEM) 2669.2 (±579.8) 2754.9 (±606.4) 2674.6 (±555.0) 2845.9 (±568.9) 2929.2 (±528.5) 2832.1 (±480.3) 2603.3 (±381.8) 2545.9 (±411.9) 2789.0 (±457.9) 2546.0 (±451.2)
Vehicle E2 100 nM
1 2 5 6 7 8 9 10 11 12 133 4
ERβ bound probe
Free Probe
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Unlabeled excess (500 or 1000x) of the same 32P-ERE oligonucleotide 
competed effectively for ERβ binding and no shift was observed when the 
receptors were incubated with a 32P-labeled scrambled DNA sequence 
Densitometry was used to quantify the band width and there were no 
statistically significant differences in the average densities of each band 
between the WT-ERβ and the phospho-mutants, indicating that 
phosphorylation at S87 or S105 does not affect ERβ binding affinity to 
consensus ERE sequences (Fig. 12). These experiments were repeated at 
minimum of 10 times to account for lane-to-lane variability between gels, and 
the average band density from all gels combined was calculated to determine 
if phospho-mutation and/or ligand affected ERE binding. I did not observe any 
statistically significant differences in average band density between vehicle or 
E2 treatments for either WT-ERβ or the ERβ phospho-mutants, which is 
consistent with my previous reports for WT-ERβ [70, 136].  
DISCUSSION 
The overall objective of these studies was to determine the 
consequences of ERβ phosphorylation on its functional capacity to act as a 
transcription factor at known promoter enhancer sites in neurons. Further, I 
hypothesized that phosphorylated ERβ would be detectable in the brain of 
aged animals, due to the potential alterations in kinase activity that can occur 
with aging [107, 142-145]. My data demonstrated the novel finding that 
phosphorylated ERβ is not only present in the brain of aged females, it is 
likely the major form of ERβ expressed in the dorsal hippocampus and 
phosphorylation tended to increase following E2 treatment. These data 
provide strong evidence for the physiological relevance of my functional in 
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vitro data, which together demonstrated that phosphorylation of ERβ at 
specific serine residues altered its ability to activate and/or repress promoter 
activity in neurons. Collectively, these data suggest that age-related changes 
in hormonal milieu and cellular kinase activity could impact the expression of 
ERβ-regulated genes, such as those mediating stress, anxiety, and cognitive 
function. 
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Table 2.  Schematic summary of reporter assay results.  Arrows indicate 
direction of change in relation to wild type ERβ. In grey are highlighted the 
instances of differences between each mutant compared to wild type ERβ. 
 
 
 
  
constitutive E2 dependent constitutive E2 dependent
wtERβ ↑ ↑↑ ↓ ↓↓
S87A ↑ ↑↑↑ − ↓↓
S87E ↑ ↑↑ − ↓↓
S105A ↑ ↑↑ − ↓↓
S105E ↑↑ ↑↑↑ − ↓
ERE (DNA binding) AP1 (Prot-Prot interaction)
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Post-translational modifications of nuclear steroid receptors have been 
widely investigated and these modifications are known to regulate their 
signaling abilities [66, 122, 125, 126]. Structurally, ERβ is similar to other 
members of the nuclear steroid receptor superfamily. The N-terminal A and B 
domains are collectively defined as the AF-1 (Activation Function-1, or N-
terminal transactivation) domain, which is a highly variable domain amongst 
the steroid receptor family and is fundamental for binding coregulatory 
proteins that assist in transcriptional activation or repression [70, 136]. 
Phosphorylation of mouse ERβ at the N-terminal serine 106 and 124 has 
previously been shown to mediate ligand independent recruitment of the 
coregulatory protein SRC-1 (steroid receptor coactivator 1) and alter its 
subsequent transcriptional activity at an ERE in COS-1 cells [128]. In those 
studies, overexpression of SRC-1 significantly increased ligand independent 
activation at an ERE site. This effect was dependent on the MAPK 
phosphorylation of S106 and S124, as the double phospho-null mutation 
(S106A/S124A) completely abolished the SRC-1-induced activation at an 
ERE. However, that study did not evaluate the effects of S106A or S124A in 
the presence of ligand (E2), or the transcriptional activity at an ERE resulting 
from a S106/S124 phospho-mimetic (i.e. mutation to glutamic acid). In my 
studies the single mutation of S87A significantly increased E2-induced 
transcription at an ERE, but there was no effect in the absence of E2. 
Moreover, there was no difference in ERE-mediated transcription when S87 
and S105 were both phospho-null (87A/105A) compared to WT-ERβ. The 
discrepancies between my results and the previously reported could be due to 
the overexpression of SRC-1 in those studies. In addition, it is possible that 
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there is a differential endogenous expression of SRC-1 in neurons or that ERs 
interact with different set of proteins depending on cell-type, resulting in 
altered signaling. 
A similar study evaluated the effects of phosphorylated human ERβ at 
S105 in cancer cell lines [81]. In that study, phosphorylation of hERβ at S105 
inhibited breast cancer cell invasion and migration in vitro, suggesting that 
phosphorylation of ERβ at S105 mediates the anti-proliferative action of ERβ 
in the breast. [81, 128]. Moreover, phosphorylated S105 ERβ has been 
detected both in benign and invasive breast cancer tissue samples using a 
human-specific phosphoS105 antibody; however no studies to date have 
detected the presence of phosphorylated ERβ in the brain. My results using 
neuronal cells showed that the phospho-mimetic S105E significantly 
increased both ligand independent and ligand dependent transcriptional 
activation at an ERE compared to WT-ERβ, whereas conversely, the opposite 
phospho-null mutation of S105A had no effect. The LBD of ERβ lies between 
residues 223-457, suggesting that   phosphorylation of S87 or S105 is unlikely 
to alter ligand binding. However, cross talk between the N-terminal and C-
terminal domain has been demonstrated, suggesting that altered ligand 
binding is a possible mechanism for phosphorylation-mediated changes in 
transcriptional activity [9]. 
It is well accepted that ERβ has lower transactivation ability at an ERE 
site compared to ERα and my data suggest that this discrepancy could be 
partly explained by the phosphorylation status of ERβ in the N-terminal AF-1 
domain [137]. For instance, phosphorylation of the N-terminal domain could 
alter the ability of ERβ to bind consensus ERE sites, thereby allowing 
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preferential binding of ERα to those same sites. This concept is supported by 
the observation that various types of post translational modifications have 
been shown to alter DNA binding in other contexts. For example, acetylation 
of ERα at two lysine residues in the DBD enhanced its ability to bind to an 
ERE [146]. By contrast, sumoylation of estrogen-related receptor alpha 
(ERRα) at two sites in the N- terminal domain did not affect its DNA binding 
ability, yet still altered its transcriptional activity [147]. My results add to 
existing evidence supporting the idea that post translational modifications in 
nuclear receptors at regions distant to the DBD alters their ability to modulate 
transcription, without affecting DNA binding.  
Perhaps the most interesting results from this study were the effects of 
ERβ phosphorylation at an AP-1 site. I have previously shown that ERβ exerts 
strong transcriptional repression at an AP-1 site in neuronal cells in the 
absence of ligand and the results presented here indicate that this might 
depend on phosphorylation of the N-terminal domain [70, 136]. The single 
mutation of either S87 or S105 completely abolished ligand independent 
inhibition of AP-1 mediated transcription compared to WT-ERβ. However, AP-
1 mediated transcription was equally repressed with WT-ERβ as it was with 
double mutations of AA, EE, or AE. Notably, only the 87E/105A mutation 
showed a significant difference from the other mutants, suggesting that S87 
phosphorylation status is the critical serine residue for mediating ERβ-induced 
repression at an AP-1 site. The precise dynamics of p38 and ERK 
phosphorylation of ERβ are unknown and the folding of singly phosphorylated 
ERβ could render the other site inaccessible to the kinase. Nevertheless, my 
data suggests that a single phosphorylation change in either S87 or S105 
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abrogates the ligand independent inhibition of AP-1, whereas no effect is 
observed due to concurrent phosphorylation of both sites. This could be 
explained by altered ERβ protein-protein interactions with Jun/Fos proteins or 
with other co-regulatory proteins recruited to the AP-1 complex, such as p160, 
based on evidence that phosphorylation alters coregulatory protein 
recruitment to ERβ [128]. The next step will be to determine which of these 
sites are phosphorylated in vivo and the precise molecular environment that 
facilitates those phosphorylation changes.  
Recently, Vivar and colleagues identified 3 classes of ERβ target 
genes and discovered that the majority of genes (453) fell into the Class I 
category, which were genes regulated by unliganded ERβ [148]. Further, the 
Class I genes showed a high enrichment for AP-1 binding sites, 
demonstrating that ligand independent repression of AP-1-mediated promoter 
activity is a common mechanism of ERβ signaling. Similarly, Zhao et al. 
showed that over 60% of ERβ interacting regions in MCF-7 breast cancer 
cells contain an AP-1 site [149] . Together these studies underscore the 
significance of my findings that ERβ ligand independent activity at an AP-1 
site is abolished when the N-terminal domain is phosphorylated. Aging in 
women results in dramatic declines in circulating estrogens raising the 
possibility that the ligand-independent actions of ERβ could play a prominent 
role in regulating gene transcription in the aging brain.  
 My studies were limited to the investigation of just one type of post-
translational modification (phosphorylation) at specific serine residues. 
However, there is evidence that other post-translational modifications of ERβ 
could also be present, such as acetylation and sumoylation, and these 
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modifications can create cross talk between different residues of the receptor. 
For example, phosphorylation at S305 on ERα inhibits subsequent acetylation 
at K303 leading to enhanced transcriptional regulation [150]. Moreover, 
phosphorylation of S94 and S106 on mERβ leads to recruitment of 
ubiquinating enzymes to the AF-1 domain resulting in enhanced degradation 
of the receptor [151]. Future studies are required to determine the precise 
mechanisms and consequences resulting from post-translational 
modifications acting in concert to modulate overall ERβ function. My in vitro 
studies were conducted using rat ERβ expression vectors in a mouse-derived 
neuronal cell line. Given the high degree of homology between rat and mouse 
ERβ, I expect that similar results would be obtained using rat neuronal cell 
lines or primary neurons derived from either species [127]. However, it is 
important to consider these results in this context as both brain-region and 
species-specific effects of ERβ have been observed [152, 153].   
 Tamoxifen (TAM) has been described as a partial antagonist due to its 
cell-type specific effects [139, 141, 154-157]. Relevant to these studies, TAM 
action in the brain has been shown to block the neuroprotective effects of E2, 
confirming that the beneficial effects of E2 are mediated by classical estrogen 
receptors [120]. In addition, TAM can activate numerous second messenger 
signaling pathways, including MAPK, thereby potentially phosphorylating and 
altering ERβ transcriptional activity [158]. My results demonstrated that TAM 
worked as an antagonist of both the WT and phosphorylated forms of ERβ by 
preventing the ligand independent increase in ERE-mediated transcription. 
Consistent with my previous studies, TAM also blocked the ligand 
independent repression of WT-ERβ at an AP-1 site. The ligand binding 
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domain (LBD) of ERα and ERβ is more conserved than other domains and X-
Ray crystallography studies have shown that both receptors bind several 
types of selective estrogen receptor modulators (SERMs), including TAM 
[159]. The structure of TAM complexed with the ERα or ERβ LBD have been 
resolved and TAM:LBD binding resulted in conformational changes that 
inhibited subsequent binding of coactivator proteins, pointing to a clear 
mechanism for TAM antagonism [160, 161].  
In summary, my results show that phosphorylation of ERβ alters its 
function in neuronal cells both in a ligand dependent and independent 
manner, and that ERβ is phosphorylated in vivo in the hippocampus. My work 
highlights the importance of further understanding the effects of post-
translational modifications on nuclear steroid receptors, as these 
modifications fundamentally alter their function as transcription factors and 
could result in clinically important physiological changes. 
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CHAPTER IV 
DIFFERENTIAL EFFECTS OF E2 ON MAPK ACTIVITY IN THE BRAIN AND 
HEART OF AGED FEMALE RATS 
PLOS ONE, February 2016 under review 
INTRODUCTION 
Clinical and basic science studies have shown that estrogens are 
neuroprotective and cardioprotective. Treatment with estrogens (ET) can 
reduce the incidence of Alzheimer disease, improve survival following 
ischemic stroke, improve learning and memory, and reduce anxiety and mood 
disorders [23-25, 36-38, 155]. Moreover, women are less likely to develop 
heart disease than men, but this advantage is lost after menopause 
presumably due to a significant reduction in circulating estrogens  [41-43]. 
Clinical correlates have indicated that the decline of circulating estrogens 
coincident with menopause leads to an increased risk of coronary heart 
disease, atherosclerosis, hypertension, stroke, neurodegenerative disease, 
cognitive decline, and mood disorders. However, the first large scale clinical 
trial designed to assess the health benefits of ET in postmenopausal women 
(The Women’s Health Initiative (WHI)) was prematurely suspended because 
of an unexpected increased risk of stroke and coronary heart disease among 
the participants [59]. 
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Subsequent analysis of the clinical data revealed that the age of the 
participants significantly affected the outcome. Women who began ET at the 
time of menopause or within 10 years had significant reductions in heart 
disease and overall mortality [162]. This observation was coined the “Timing 
Hypothesis”, and postulated that ET administration is beneficial for early 
postmenopausal women, but detrimental in late postmenopausal women. 
Importantly, the underlying molecular mechanisms for these observations 
remain undetermined. 
The actions of estrogens are mediated primarily by estrogen receptor 
(ER) α and ERβ. Both receptors can mediate the neuroprotective and 
cardioprotective effects of estrogens [16, 25, 45, 46, 51, 155, 163].  Estrogens 
bind ERs to regulate gene transcription through classical genomic pathways, 
or by modulating cell signaling pathways such as the MAPKs (mitogen 
activated protein kinases) ERK (extracellular signal-regulated kinase) and p38 
[113, 164-170].  Moreover, aging alone modulates similar cell signaling 
pathways independent of estrogens [107, 110, 113, 143, 144, 169, 171, 172]. 
One possibility for these age-related changes is that MAPKs are sensitive to 
proinflammatory and oxidative stimuli, which are increased with age [173].  
These converging data suggest that MAPK signaling could be a molecular 
mechanism underlying the discrepant effects of ET in postmenopausal 
women. 
MAPK family members are activated by phosphorylation at their 
threonine-x-tyrosine phosphorylation site motif. MAPKs activation is the last of 
a three step activation cascade from MAP3K to MAP2K to MAPK. Once 
phosphorylated (i.e. activated) they in turn phosphorylate substrate proteins at 
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serine or threonine residues in specific recognition sequences [91]. The 
knowledge of the activators, substrates and functions of MAPKs are ever 
expanding, however when they were first discovered they were deemed 
stress-activated protein kinases (SAPKs) because of their responsiveness to 
toxins, physical stresses and inflammatory cytokines [92, 94]. Generally, 
ERK1/2 are preferentially activated in response to growth factors and 
extracellular stimuli, while p38 are more responsive to stresses such as 
osmotic shock, ionizing radiation and cytokines [95]. MAPKs can be present in 
several cell compartments, such as the nucleus, the cytoplasm and close to 
the cell membrane, thereby allowing them to integrate signals to coordinate a 
variety of physiological responses including mitosis, apoptosis, survival, 
cellular differentiation, and gene expression.  
Activated MAPKs target a wide pool of proteins due to sequence 
variation in the conserved phosphorylation motif and in the availability of 
docking sites on their protein targets.  The strongest requirement is the 
presence of a proline directly at the C- Terminus of the target protein 
phosphorylation site and this feature is a shared requirement for both p38 and 
ERK kinases. Another characteristic feature differentiating the downstream 
effects of MAPKs is the presence of docking sites in their substrates; the best 
characterized being D-sites and F-sites. ERK and p38 phosphorylate different 
target proteins, leading to differential downstream effects because of their 
heterogeneous recognition motif and respective preference for D- and F- sites 
in the targets [93]. Interestingly, 30% of human proteins have at least one 
MAPK phosphorylation site, yet few have the required docking sites to 
facilitate phosphorylation by MAPK family members.  
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The overall goal of this study was to quantify the total expression and 
activation of MAPKs (ERK and p38) in the brain and heart of aged female rats 
subjected to a paradigm designed to model the tenets of the Timing 
Hypothesis (see Fig.13). I hypothesized that the combination of age and low 
circulating estrogens alters the expression and activation of p38 and ERK 
kinases in the brain and heart. To test this hypothesis, I used a rat model of 
surgically-induced menopause and quantified changes in kinase activity 
following varying lengths of E2 deprivation.  My data revealed age- and E2-
dependent effects on kinase activity suggesting a potential mechanism 
explaining the variable effects of E2 following menopause.  
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Figure 13. Diagram of the animal paradigm. Female Fisher 344 rats were 
ovariectomized at day 0 (= 18 months old) and subjected to increasingly 
longer periods of hormone deprivation (1, 4, 8, and 12 weeks). Following the 
assigned length of deprivation, animals were treated with either vehicle 
(safflower oil) or 17-estradiol (E2; 2.5 μg/kg) by subcutaneous injection once 
daily for 3 consecutive days (n=10/treatment group/deprivation time). Animals 
were euthanized 24 hours following the last treatment. 
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RESULTS 
LENGTH OF E2 DEPRIVATION AND SUBSEQUENT E2 TREATMENT 
ALTERS ERK AND P38 KINASE ACTIVITY IN THE BRAIN AND HEART OF 
AGED FEMALE RATS. 
I first tested whether the effects of E2 treatment on ERK and p38 
kinase activity would depend on the length of time aged animals were 
deprived of circulating E2 (i.e. time post-ovx). I measured the ratio of 
phosphorylated and total ERK and p38 proteins as a measure of kinase 
activity in 3 distinct brain regions (hypothalamus, dorsal hippocampus, ventral 
hippocampus) and in the left ventricle of the heart. The hypothalamus 
regulates homeostasis, thermoregulation and stress response which are often 
dysregulated in post-menopausal women [174]. The hippocampus is 
functionally divided in two regions, dorsal and ventral [175] and both regions 
express ERs. The dorsal hippocampus (DH) mediates cognitive functions, 
while the ventral hippocampus (VH) mediates processes associated with 
emotional memory and stress [175]. In addition, I focused on the heart 
because the likeliness of developing heart disease increases in women post-
menopause, and sex differences in cardiovascular disease are well 
characterized. The left ventricle (LV) is the main pumping chamber of the 
heart and it is most commonly subjected to diseases that accompany aging, 
such as hypertrophy. Estrogen receptors are highly expressed in the LV and 
the cardioprotective effects of E2 treatment are evident in the LV [163, 176, 
177]. 
Brain – Hypothalamus. A two-factor ANOVA analysis revealed a 
significant interaction between length of E2 deprivation and subsequent E2 
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treatment (all F-values reported in Table 3), demonstrating that the effects of 
E2 are dependent on when it is administered following prolonged periods of 
E2 deprivation. Total ERK protein increased in E2-treated animals at the 12-
week post-OVX time point, yet total protein in both groups remained stable at 
all other time points (Fig. 14A). Conversely, E2 treatment had a dramatic 
effect on the amount of phosphorylated ERK, which is an indicator for the 
active form of the protein. E2 treatment significantly decreased the amount of 
phosphorylated ERK to levels that were barely above detection at the 8- and 
12-week post-OVX time points (Fig. 14B).  The ratio of phosphorylated ERK 
to total ERK protein was significantly lower at all time points in E2-treated 
animals (Fig. 14C), representing a large magnitude shift from baseline 
compared to vehicle-treated controls (Fig. 14D).  
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Figure 14. Effects of age and E2 treatment on ERK protein expression and 
activation in the hypothalamus. Total ERK protein (A), phosphorylated ERK 
(B), calculated ratio of phospho:total-ERK (C), and percent change from 
vehicle following E2 treatment (D). Data are expressed as mean fold change 
 SEM compared to vehicle-treated animals at one week post-OVX (A-C). An 
* indicates statistically significant difference from 1-week time point; # 
indicates significant difference within the same time point. 
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By stark contrast to ERK activity in the hypothalamus, total p38 protein 
was unchanged over time and with treatment (Fig. 15A); however 
phosphorylated p38 increased 3-fold at the 12-week time point in both vehicle 
and E2-treated groups (Fig. 15B). The ratio of phospho:total p38 was not 
altered by E2 treatment (Fig. 15C), however it is notable that it was increased 
by 170% in the E2-treated animals at 1-week post-OVX compared to vehicle 
treated animals.  
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Figure 15. Effects of age and E2 treatment on p38 protein expression and 
activation in the hypothalamus. Total p38 protein (A), phosphorylated p38 (B), 
calculated ratio of phospho:total-p38 (C), and percent change from vehicle 
following E2 treatment (D). Data are expressed as mean fold change  SEM 
compared to vehicle-treated animals at one week post-OVX (A-C). An * 
indicates statistically significant difference from 1-week time point; # indicates 
significant difference within the same time point. 
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 Brain - Dorsal hippocampus. I then measured ERK and p38 protein 
and phosphoprotein in the dorsal hippocampus (Figs.16, 17). Similar to the 
results observed in the hypothalamus, a two-factor ANOVA revealed a 
significant interaction between length of E2 deprivation (i.e. time post-OVX) 
and subsequent E2 treatment (Table 3). E2 treatment significantly decreased 
phosphorylated ERK at the 1-week time point, yet there were no changes in 
total ERK protein in either group (Fig. 16A, B). The ratio of phospho:total ERK 
was significantly lower than vehicle-treated animals at 1-week post-OVX (Fig. 
16C) and the overall levels of phosphoERK were consistently lower in E2-
treated animals across the treatment paradigm (Fig. 16D).  
  
 
 
 
 
71 
 
Figure 16. Effects of age and E2 treatment on ERK protein expression and 
activation in the dorsal hippocampus. Total ERK protein (A), phosphorylated 
ERK (B), calculated ratio of phospho:total-ERK (C), and percent change from 
vehicle following E2 treatment (D). Data are expressed as mean fold change 
 SEM compared to vehicle-treated animals at one week post-OVX (A-C). An 
* indicates statistically significant difference from 1-week time point; # 
indicates significant difference within the same time point. 
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Next, I measured p38 expression and activation in the dorsal 
hippocampus (Fig. 17). A two-factor ANOVA analysis revealed a significant 
main effect of time post-OVX, yet no significant interaction suggesting the two 
variables were not dependent on each other (Table 3).  Similar to ERK, E2 
treatment significantly inhibited phospho-p38 levels 1 week post-OVX (Fig. 
17B), yet the ratio of phospho:total p38 was not significantly different at any 
time point (Fig. 17C, D). 
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Figure 17. Effects of age and E2 treatment on p38 protein expression and 
activation in the dorsal hippocampus. Total p38 protein (A), phosphorylated 
p38 (B), calculated ratio of phospho:total-p38 (C), and percent change from 
vehicle following E2 treatment (D). Data are expressed as mean fold change 
 SEM compared to vehicle-treated animals at one week post-OVX (A-C). An 
* indicates statistically significant difference from 1-week time point; # 
indicates significant difference within the same time point. 
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 Brain – Ventral hippocampus. A two-factor ANOVA revealed a 
significant interaction between length of E2 deprivation and subsequent E2 
treatment, similar to the results from the other brain regions (hypothalamus 
and dorsal hippocampus) (Table 3). Specifically, total ERK protein was 
significantly decreased at 4 weeks post-OVX in both vehicle and E2-treated 
animals, and these levels increased back to the levels observed at 1-week 
post-OVX by the 8 and 12-week time points (Fig. 18A). E2 treatment 
decreased phosphoERK by 70%, at 1-week post-OVX, but both vehicle and 
E2-treated animals had significantly lower levels of phospoERK at the 4 and 8 
weeks post-OVX time points (Fig. 18B). Interestingly, the ratio of 
phospho:total ERK was not different between treatment groups or with longer 
periods of E2 deprivation (Fig. 18C) and this was likely due to parallel 
changes that occurred in total available ERK protein. The strong inhibitory 
action of E2 on ERK activation was only present at the early E2 deprivation 
time point (1 week post-OVX), while at later time points (4 and 8 weeks post-
OVX) E2 treatment increased ERK activation (Fig.18D).  
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Figure 18. Effects of age and E2 treatment on ERK protein expression and 
activation in the ventral hippocampus. Total ERK protein (A), phosphorylated 
ERK (B), calculated ratio of phospho:total-ERK (C), and percent change from 
vehicle following E2 treatment (D). Data are expressed as mean fold change 
 SEM compared to vehicle-treated animals at one week post-OVX (A-C). An 
* indicates statistically significant difference from 1-week time point; # 
indicates significant difference within the same time point. 
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There were few observed differences between treatment groups or with 
length of E2 deprivation in total or phospho-p38 levels (Fig. 19A, B). A two-
factor ANOVA revealed no significant interaction between the two factors, but 
there was a significant main effect of time post-OVX (Table 3). E2 treatment 
significantly decreased the amount of total p38 protein at 12-weeks post-OVX 
(Fig. 19A) without any corresponding change in the levels of phospho-p38 
(Fig. 19B). The ratio of phospho:total p38 was also significantly decreased 
after 8 weeks of E2 deprivation, but there was no difference between 
treatment groups (Fig. 19C). Overall, E2-treated animals had lower 
phosphorylated levels of p38 compared to vehicle treated animals until the 12-
week post-OVX time point. At 12 weeks post-OVX there was a dramatic 
reversal with E2-treated animals having 88% higher levels of phosphorylated 
p38 compared to vehicle-treated animals (Fig. 19D). 
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Figure 19. Effects of age and E2 treatment on p38 protein expression and 
activation in the ventral hippocampus. Total p38 protein (A), phosphorylated 
p38 (B), calculated ratio of phospho:total-p38 (C), and percent change from 
vehicle following E2 treatment (D). Data are expressed as mean fold change 
 SEM compared to vehicle-treated animals at one week post-OVX (A-C). An 
* indicates statistically significant difference from 1-week time point; # 
indicates significant difference within the same time point. 
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Heart – Left ventricle. Total ERK protein levels increased 12 weeks 
post OVX in the E2-treated animals compared to the vehicle-treated animals 
(Fig. 20A). In contrast to results obtained in the brain, length of E2 deprivation 
(i.e. age alone) had the most striking effect on ERK activation, while E2 
treatment had a modest, yet statistically significant effect. Moreover, a two-
factor ANOVA revealed a significant interaction between length of E2 
deprivation and subsequent E2 treatment (Table 3), demonstrating that the 
effects of E2 replacement on ERK activity are altered following prolonged 
periods of time post-OVX in both the heart and brain. Specifically, phospho-
ERK significantly decreased in both vehicle- and E2-treated groups at 4 and 8 
weeks, yet there was a dramatic rebound in phospho-ERK in the E2-treated 
animals after 12 weeks of E2 deprivation (Fig. 20B). However, after 
comparing the ratio of active to total ERK it is clear that the length of E2 
deprivation was the most important factor regulating ERK activity (Fig. 20C), 
as both treatment groups showed significant declines (80% decrease) at 4 
and 8 weeks that returned to baseline by 12 weeks (Fig. 20D). Notably, E2 
treatment led to even further declines in active ERK (to nearly undetectable 
levels) at 4 and 8 weeks post-OVX (Fig. 20D).  
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Figure 20. Effects of age and E2 treatment on ERK protein expression and 
activation in the left ventricle. Total ERK protein (A), phosphorylated ERK (B), 
calculated ratio of phospho:total-ERK (C), and percent change from vehicle 
following E2 treatment (D). Data are expressed as mean fold change  SEM 
compared to vehicle-treated animals at one week post-OVX (A-C). An * 
indicates statistically significant difference from 1-week time point; # indicates 
significant difference within the same time point. 
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Total p38 protein levels were not significantly altered in the heart in my 
paradigm (Fig. 21A). However, a two-factor ANOVA analysis revealed a 
significant interaction between the two factors, E2 treatment and length of 
time post-OVX, on the levels of phospho-p38 in the heart. Consistent with the 
observations for ERK, p38 activation decreased with longer periods of 
deprivation post-OVX regardless of treatment in the heart (Fig. 21C).  There 
was a strong main effect of time post-OVX, as the phospho:total p38 declined 
by more than 40% by the 4-week time point (Fig. 21C). These lower levels 
were stable up to 12 weeks post-OVX, in E2 and vehicle treated animals, in 
contrast with ERK whose activation levels were restored 12 weeks post-OVX. 
Although E2-treatment significantly decreased phospho-p38 at 8 weeks post-
OVX, this effect did not have a major impact on the amount of active p38 (Fig. 
21B, C, D). 
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Figure 21. Effects of age and E2 treatment on p38 protein expression and 
activation in the left ventricle. Total p38 protein (A), phosphorylated p38 (B), 
calculated ratio of phospho:total-p38 (C), and percent change from vehicle 
following E2 treatment (D). Data are expressed as mean fold change  SEM 
compared to vehicle-treated animals at one week post-OVX (A-C). An * 
indicates statistically significant difference from 1-week time point; # indicates 
significant difference within the same time point. 
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LENGTH OF E2 DEPRIVATION AND SUBSEQUENT E2 TREATMENT 
ALTERS ERK AND P38 MRNA EXPRESSION 
To determine if steady-state mRNA expression paralleled the observed 
changes in protein levels, I measured ERK (Fig. 22) and p38 (Fig. 23) mRNA 
in each brain region and in the left ventricle of animals subjected to my E2-
deprivation paradigm. A two-factor ANOVA revealed statistically significant 
differences between treatment groups in the hypothalamus (Fig. 22A) and the 
heart (Fig. 22D), but not in either region of the hippocampus (Fig.22B, C). 
Treatment with E2 increased ERK mRNA 1-week post-OVX, (Fig. 22A, 
dashed line), however ERK mRNA levels increased progressively over time 
and this age-related increase was prevented by E2 treatment (Fig. 22A). 
Similarly, prolonged periods of E2 deprivation increased ERK mRNA in the 
heart and this was significantly decreased following E2-treatment at the 12 
weeks post-OVX time point (Fig. 22D).  
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Figure 22. Effects of age and E2 treatment on ERK mRNA expression.  ERK 
mRNA was measured using RT-qPCR in the hypothalamus (A), dorsal 
hippocampus (B), ventral hippocampus (C), and left ventricle (D). Data are 
expressed as mean fold change  SEM compared to vehicle-treated animals 
at one week post-OVX. ). An * indicates statistically significant difference from 
1-week time point; # indicates significant difference within the same time 
point. 
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Expression of p38 mRNA levels were also statistically different 
between groups subjected to my E2-deprivation paradigm (Fig. 23). In the 
hypothalamus (Fig. 23A) p38 expression was significantly increased 4 and 8 
weeks post-OVX, with no significant effect of E2 treatment. In the dorsal 
hippocampus a significant main effect of time, but not treatment was detected 
and pairwise comparisons did not reveal statistically significant changes 
between groups (Fig. 23B).   A significant interaction of treatment and time 
post-OVX was detected in the ventral hippocampus (Table 3), where E2 
treatment significantly reduced p38 mRNA at the 12-week time point (Fig. 
23C). There were no differences between groups in p38 mRNA expression in 
the heart (Fig. 23D). 
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Figure 23. Effects of age and E2 treatment on p38 mRNA expression. P38 
mRNA was measured using RT-qPCR in the hypothalamus (A), dorsal 
hippocampus (B), ventral hippocampus (C), and left ventricle (D). Data are 
expressed as mean fold change  SEM compared to vehicle-treated animals 
at one week post-OVX. ). An * indicates statistically significant difference from 
1-week time point; # indicates significant difference within the same time 
point. 
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ERK AND P38 ACTIVATION ARE DIFFERENTIALLY REGULATED BY ERα 
AND ERβ 
The differential effects of ERβ and ERα on MAPKs signaling have been 
previously reported in different experimental systems, and I detected both 
forms of the receptor in my samples [178, 179]. Therefore, in order to 
determine the contribution of each estrogen receptor, I treated a set of 18 mo 
Fisher 344 with the ERβ or ERα specific agonists DPN and PPT, 1 week post 
OVX to compare with the vehicle or E2 treated animals at the same time 
point. In Fig. 24, the ratio of phosphorylated ERK and total ERK was 
measured via Western blot in samples from the hypothalamus (A), dorsal 
hippocampus (B), ventral hippocampus (C) and heart (D). In the 
hypothalamus, E2 treatment 1 week post OVX determined a significant 
inhibition of ERK activation, which was replicated in animals treated with the 
ERα agonist PPT. The ERβ specific agonist DPN did not significantly alter the 
activation of ERK, indicating that in the hypothalamus ERα is the main 
mediator of the inhibition of ERK activity. In the dorsal hippocampus E2 was 
found to inhibit ERK activation 1 week post OVX, and in panel B of Fig. 24 
ERβ and ERα specific agonists show a similar effect. All treatments 
significantly inhibited ERK activation compared to vehicle treated animals. No 
significant changes in ERK activation were detected in the ventral 
hippocampus when animals were treated with E2, DPN or PPT. Although a 
trend to a decrease was observed in the E2 treated animals. In the heart, E2 
treatment does not alter ERK activation 1 week post OVX and neither do DPN 
PPT (see Fig. 24 D). 
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Figure 24. ERK activation is differentially regulated by ER isoform specific 
agonists. Ratio of phospho:totalERK in the hypothalamus (A), dorsal 
hippocampus (B), ventral hippocampus (C), heart (D) of 18 months old rats 
treated with V, E2, DPN (ERβ agonist) or PPT ( ERα agonist) 1 week post 
OVX. Total and phosphorylated ERK were measured via Western blot; ratio of 
the two is represented here. Fold change compared to vehicle-treated 
animals. An * indicates statistically significant difference between groups 
using one-way ANOVA p<0.05 (n=4/6 animals per group) 
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The ratio pf phosphorylated p38 and total p38 was calculated following 
Western blot analysis in the hypothalamus (A), dorsal hippocampus (B), 
ventral hippocampus (C) and heart (D) as shown in Fig. 25.  In the 
hypothalamus PPT treatment alone significantly increased p38 activation 5 
fold, while in E2 and DPN treated animals levels were similar to the vehicle 
group. The fact that E2 alone does not increase p38 activation while PPT 
does might be reflective of E2 binding to heterodimers.  The other regions did 
not show any statistically significant effect of DPN or PPT on p38 activation. 
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Figure 25. p38 activation is differentially regulated by ER isoform specific 
agonists. Ratio of phospho:total-p38 in the hypothalamus (A), dorsal 
hippocampus (B), ventral hippocampus (C), heart (D) of 18 months old rats 
treated with V, E2, DPN (ERβ agonist) or PPT ( ERα agonist) 1 week post 
OVX. Total and phosphorylated p38  were measured via Western blot; ratio of 
the two is represented here. Fold change compared to vehicle-treated 
animals. An * indicates statistically significant difference between groups 
using one-way ANOVA p<0.05 (n=4/6 animals per group) 
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Consistent with what has been observed throughout this study, ERK 
activity was more sensitive to my animal paradigm than p38. Interestingly, I 
found that the ER isoforms differentially alter kinase activity. Overall I found 
that in the hypothalamus ERα plays a more important role on MAPKs 
regulation. I have shown that E2 treatment leads to inhibition of ERK likely by 
activating ERα. Furthermore, stimulation of ERα but not ERβ activates p38. 
However, in the dorsal hippocampus both receptor specific agonists had the 
same effects as E2. 
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Table 3. F-values and p values from two factor ANOVA analysis.
Hypothalamus
Interaction Treatment X Time Main Effect of Treatment Main effect of Time
ERKmRNA No No Yes F(3, 37)= 3.320, p<0.001
ERK protein No No No
phosphoERK No Yes F (1,39)= 18.226 p<0.001 No
Ratio No Yes F (1,44)= 15.670 p<0.001 No
p38mRNA No No Yes F(3, 35)= 6.474, p= 0.001
p38 protein No No Yes F( 3,36)= 11.346, p<0.001
phospho p38 No No No
Ratio Yes F (3,33)= 3.558, p=0.025 No Yes F (3,36)= 3.821, p=0.018
Dorsal Hippocampus
Interaction Treatment X Time Main Effect of Treatment Main effect of Time
ERKmRNA No No Yes F (3,32)= 4.105, p=0.014
ERK protein No No No
phosphoERK Yes F (3,39)= 4.012, p=0.014 No No
Ratio No No No
p38mRNA No No Yes F(3, 33)= 4.214, p= 0.013
p38 protein No No No
phospho p38 No No Yes F(3, 37)= 6.586, p= 0.001
Ratio No No Yes F(3, 37)= 5.653, p= 0.003
Ventral Hippocampus
Interaction Treatment X Time Main Effect of Treatment Main effect of Time
ERKmRNA No No No
ERK protein Yes F (3, 31)= 2.915, p= 0.050 Yes F (1, 31)= 6.294 , p= 0.018 Yes F (3, 31)= 12.942, p<0.001
phosphoERK Yes F (3, 34)= 3.205, p= 0.035 Yes F (1, 34)= 4.806 , p= 0.035 Yes F (3, 34)= 3.955, p= 0.016
Ratio Yes F (3, 35)= 3.177, p= 0.037 No No
p38mRNA Yes F (3, 37)= 6.621, p= 0.003 Yes F (1, 37)= 7.783, p= 0.008 Yes F (3, 37)= 6.493, p= 0.001
p38 protein Yes F (3, 33)= 4.624, p= 0.008 No Yes F (3, 33)= 3.583 p= 0.024
phospho p38 No No Yes F (3, 34)= 4.822, p= 0.007
Ratio Yes F (3, 32)= 3.727, p= 0.021 No Yes F (3, 32)= 6.713, p= 0.001
Heart
Interaction Treatment X Time Main Effect of Treatment Main effect of Time
ERKmRNA Yes F (3, 35)= 3.385, p= 0.029 No Yes F (3, 35)= 8.502, p<0.001
ERK protein Yes F (3, 58)= 4.430, p= 0.007 No Yes F (3, 58)= 6.806, p=0.001
phosphoERK Yes F (3, 59)= 5.227, p= 0.003 Yes F (1, 59)= 4.893, p= 0.031 Yes F (3, 59)= 20.089, p<0.001
Ratio No No Yes F (3, 60)= 14.834, p<0.001
p38mRNA No No Yes F(3, 35)= 2.385, p<0.001
p38 protein No No No
phospho p38 Yes F (3, 44)= 3.502, p= 0.023 No No
Ratio No No Yes F(3, 51)= 5.299, p= 0.003
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DISCUSSION 
MAPKs are central components of second messenger signaling 
pathways and are ubiquitously expressed in all cell types, therefore the 
functional implications for these findings are widespread. Here, I report the 
novel findings that E2 treatment differentially affects ERK and p38 activation, 
as well as total protein and mRNA expression, in the brain and the heart 
dependent on age and length of time following E2 deprivation (i.e. 
OVX/menopause). Importantly, length of E2 deprivation was a critical factor in 
every parameter analyzed. For example, ERK and p38 were significantly less 
active 4 or more weeks following OVX regardless of treatment in the heart, 
possibly reflecting an age-related change. Age has been shown to both 
increase and decrease MAPKs activation, depending on tissue analyzed, sex, 
age and species of the animal model, as well as experimental design [106, 
107, 180, 181].  For instance, Li et al. hypothesized that p38, a key regulator 
of pro-inflammatory cytokine biosynthesis, would be activated by the low 
grade inflammation that is associated with the aging process. They observed 
increased levels of inflammatory markers accompanied by doubling in p38 
activation in the lung and whole brain homogenate of old (20 mo.) compared 
to young (2 mo.) C57BL/6J mice [106]. Similarly, p38 expression and activity 
was increased by 2.5 fold in the brain of 26 mo. compared to 2 mo. Fisher 344 
rats [107]. These findings align with my results in the hypothalamus where 
p38 had a 2.5 fold increase 12 weeks post-OVX, regardless of treatment. 
However, these results were brain region specific, as I did not observe age-
related changes for phospho-p38 in other brain regions analyzed.  
Perhaps most intriguing was the observation that E2-induced changes 
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in activated ERK and p38 were prolonged, given that the last dose of E2 was 
administered 24 hours before euthanasia. The prevailing view is that the non-
genomic actions of E2 occur within minutes and the effects on MAPK 
phosphorylation are transitory. Indeed, this has been observed repeatedly in 
vitro, however accumulating evidence suggests that the in vivo regulation of 
MAPKs is more complex [110, 114, 169, 182-187]. One possibility is that E2, 
acting through classical genomic pathways, altered cellular components 
required for maintaining balance between active and inactive MAPKs.  For 
example, crosstalk between phosphorylation and ubiquitination pathways can 
exert long-term changes in cellular processes through multiple feedback loops 
that ultimately impact apoptosis and cell proliferation [188]. Moreover, I along 
with others have shown that E2 can regulate microRNAs in the brain and the 
heart, and some of these miRNAs could target components of MAPK 
signaling pathways [179, 189-192] providing a putative mechanism for 
sustained activation of these kinases. These results were further corroborated 
in a 2013 study which showed E2 could regulate long-term activation of 
MAPKs by altering expression of microRNAs that silence upstream inhibitors 
of ERK activation [192]. The findings herein combined with other published 
studies suggest that E2 can exert prolonged changes in MAPKs activation 
that cannot be explained by the acute non-genomic actions of E2 alone. 
The significant interactions observed between the two factors of time 
and E2 treatment for ERK, but not p38, in nearly every brain region and in the 
heart could have important functional ramifications for understanding the 
physiological consequences of ET in postmenopausal women. Specifically, 
the timing of E2 treatment would not be expected to impact p38 signaling in 
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these tissues, despite the fact p38 activity was independently altered by E2 
and age. Conversely, activated ERK was mainly decreased following E2 
treatment and the timing of E2 treatment dictated the magnitude of decline. 
Activation of ERK induces downstream signaling pathways that mediate both 
neuro- and cardioprotection. For instance, the formation of dendritic spines 
was increased by E2 treatment through ERK-mediated mTOR (mammalian 
target of rapamycin) and this E2-induced synaptic plasticity is a key 
mechanism underlying memory consolidation and storage [193].  Similarly, 
activated ERK mediates cardioprotective pathways in the heart and phospho-
ERK is increased by E2 in young adult rat cardiomyocytes [110, 170, 194-
196]. The E2-induced decrease of activated ERK in the brain and heart 
following longer periods post-OVX reveal a putative mechanism for memory 
decline and reduced cardioprotection following ET in late postmenopausal 
women. 
Increased estrogen receptor-mediated gene transcription is the most 
likely explanation for my observed increases in total ERK and p38 protein 
levels. Indeed, I found that the mRNA levels of both kinases were significantly 
altered by E2 treatment and length of deprivation in the brain and heart. 
Sequence analysis of the ERK and p38 gene promoters revealed an 
abundance of binding sites for several transcription factors such as NF-kB 
and GATA families as well as multiple estrogen response elements (ERE) 
[197]. The canonical actions of ERs are through direct ERE binding, however 
ERs can also regulate transcription by tethering to other transcription factors, 
such as members of the Jun and Fos families acting at AP-1 sites (activator 
protein-1) [198]. Notably, there are 28 and 34 identified AP-1 sites within 2000 
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bp upstream of the p38 and ERK translation start sites, respectively. These 
data demonstrate that there are multiple mechanisms for E2 to regulate ERK 
and p38 transcription directly at the level of the gene promoter.  
In the last decade, sophisticated genomic and proteomic tools have 
allowed for the quantitative molecular analysis of complex biological samples. 
These experiments revealed low correlations between mRNA and protein 
levels in many samples [199]. Similarly, changes in ERK and p38 protein 
levels did not tightly correlate with their altered mRNA levels in my paradigm. 
This suggests that age and/or E2 treatment can regulate compensatory 
factors that affect protein translation or stability. For example I observed a 3 to 
5- fold increase of ERK mRNA following prolonged E2 deprivation in the 
hypothalamus, yet total ERK protein was unchanged. This could be partly 
explained by the semi-quantitative nature of the techniques (i.e. Western blot). 
Alternatively, this observation could be due to increased mRNA turnover or 
translational inhibition. Several mechanisms of post transcriptional regulation 
of mRNA have been described and microRNAs are interesting example of 
regulatory molecules that can repress target mRNA translation [200]. My 
recent work demonstrated that microRNA expression is differentially regulated 
by prolonged E2 deprivation and subsequent E2 treatment using this same 
animal treatment paradigm in aged rats [179, 190]. In line with the current 
findings, several of those E2-regulated microRNAs have the potential to inhibit 
p38 and ERK mRNA translation, resulting in decreased protein levels. I also 
identified a subset of microRNAs that are differentially regulated by E2 in 
young (3 mo.) vs. old (18 mo.) rats using a microRNA microarray platform 
[190]. Bioinformatics pathway analyses revealed that the MAPK pathway was 
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predicted as the most represented cellular pathway targeted by the 
microRNAs I identified as E2 regulated [190]. Regulation of microRNAs is just 
one possible explanation for the discrepancies seen between mRNA and 
protein levels in complex biological samples.  
I also sought to determine which ERs might be mediating the effects on 
MAPKs activity in my animal paradigm. My group has recently demonstrated 
that  in animals subject to my experimental paradigm both ERα and ERβ are 
expressed in the brain regions in analysis and in the heart throughout all time 
points and treatments [178, 201]. Furthermore I have analyzed the expression 
of ERβ2, a splice variant of ERβ, which is a constitutively active form of the 
receptor, and found that it was regulated by estrogen deprivation following 
OVX as well as E2 [178]. Here I have determined that 1 week post OVX E2 
significantly inhibits ERK activation, likely via ERα whose activation also 
significantly inhibited ERK activation. Similarly p38 activation was also 
activated by E2 treatment and ERα agonist PPT in the hypothalamus, while 
ERβ agonist DPN had no effect. In the dorsal hippocampus however both 
ERα and ERβ agonists inhibited ERK activation as did E2. Isoform specific 
effects of ERs are known, however this is the first in vivo analysis of MAPKs 
regulation in the brain and heart.  
 Despite the understanding of the importance of the time of initiation of 
ET in women for neuroprotection and cardioprotection gained from clinical 
studies, clear mechanistic insight is still lacking. I designed my study to model 
a main tenet of the timing hypothesis, as based on clinical observations [59, 
202, 203]. One limitation is that rodent reproductive senescence is not 
comparable to the menopausal transition in women [204, 205]. However, the 
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surgically-induced menopause model used in rodents is the most accurate 
method to determine the length of time following total ovarian hormone 
depletion, and surgically-induced menopause is clinically relevant for some 
women. I have also demonstrated previously that 18 months of age is a 
physiologically relevant comparison to human in this strain of rat (Fisher 344), 
although Sprague Dawley rats demonstrate much earlier reproductive 
senescence [178]. The concepts referred as “window of opportunity” or “timing 
hypothesis” emerged from clinical studies that found that age of ET initiation 
determined the successful outcome of the study. Indeed estrogens reduced 
risk of cognitive decline and dementia when administered to women in early 
stage of menopause [56]. Postmenopausal women receiving ET in a 2012 
Danish study also had significantly reduced risk of mortality and heart failure, 
without an increased risk of breast cancer or stroke [57].  The WHI ET follow-
up showed that women 50-59 of age had statistically significant reduction in 
coronary heart disease (Hazard Ratio HR of 0.59), myocardial infarction (HR 
0.54) and overall mortality (0.73) [58]. These are only a few examples of how 
cognitive and cardiovascular health of menopausal women can be improved if 
ET is started at the right time (i.e. in early menopause). My data highlights 
MAPKs as a possible focus of further analysis, as these kinases are critical 
regulators of cell signaling pathways.
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CHAPTER V 
QUANTITATIVE MASS SPECTROMETRY FOR IN VIVO ANALYSIS OF 
PHOSPHORYLATED ERβ 
INTRODUCTION 
Phosphorylation of ERβ significantly alters its function as a 
transcription factor as shown in Chapter III [206]. ERβ can be phosphorylated 
in its N-terminal domain at two sites, S87 and S105. This was shown first by 
mutating mouse ERβ in the homologous Serines into Alanines and performing 
in vitro phosphorylation with radioactive p32ATP [128]. The Mutant ERβ failed 
to incorporate p32ATP, indicating that S87 and S105 are phosphorylated at 
those sites. Separate groups have found that ERβ can be phosphorylated in 
vitro by the MAPKs ERK1, ERK2, p38 but not Src or PKA [81, 128]. Later, 
phosphorylation of purified human ERβ at S105 was verified following in vitro 
phosphorylation using mass spectrometry (MS) [81]. I have extended these 
findings by demonstrating detection of phosphorylated ERβ, in vivo, in the 
brain and heart of aged rats using PhosTagTM immunoblotting (Chapter III). 
While this technique allowed for detection of phosphorylated forms of ERβ, 
the site or sites at which the phosphates are attached cannot be determined 
with this technique. Importantly, site specific modifications altered ERβ 
function, as shown in Chapter III, therefore the identification of distinct 
phosphorylated residues in vivo is a critical next step.  
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Phosphorylation of ERβ in vivo was also detected using antibodies 
directed against the phosphoS105ERβ peptide through immunohistochemical 
staining of human breast tissue samples [81]. While this is a positive 
indication of the presence of phosphoS105ERβ in human breast, antibody 
based assays are often misleading when studying ERβ. Indeed a thorough 
analysis of nine antibodies available revealed that while some do recognize 
ERβ used in certain techniques, most lack specificity or only work correctly in 
a specific application [207]. The lack of reliable tools for investigating ERβ in 
vivo is a recurring theme in the field and most experts attribute this to the 
partially unfolded state of the N-terminal domain of ERβ [208-211]. The 
dynamic structural behavior of ERβ gives it the ability to rapidly interact with 
different coregulatory proteins, localize to different intracellular organelles and 
transition on and off the DNA quickly, overall determining its functional 
heterogeneity that makes it an important target of investigation.  
The activity of the MAPKs p38 and ERK, the kinases that have been 
shown to phosphorylate ERβ, is sensitive to aging and estrogen treatment. 
Indeed the findings described in Chapter IV demonstrated that the length of 
estrogen deprivation prior to estrogen treatment altered MAPKs activation in 
the brain and heart of aged rats. Therefore, it is likely that levels of 
phosphorylated ERβ are different in the tissues of rats that underwent the 
estrogen deprivation paradigm. ERβ mediates important neuroprotective and 
cardioprotective effects of estrogens and its phosphorylation has functional 
consequences as shown in Chapter III. Therefore it is pivotal to detect and 
compare levels of phosphorylated ERβ in brain and hearts. 
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 The experimental approach I chose was to use Multiple Reaction 
Monitoring (MRM) (also referred to as Selected Reaction Monitoring or SRM); 
a mass spectrometry based method that allows for detection and 
quantification of low abundance peptides in complex samples. Briefly, during 
an MRM experiment a predefined peptide of interest is detected using a Triple 
Quadrupole mass spectrometer. By mixing a known amount of a peptide 
identical to the target peptide but incorporating heavy isotopes, the amount of 
unknown peptide can be readily quantified. Further, using heavy labelled 
peptides that are phosphorylated at the site of interest allows for the 
quantification of the phosphorylated form of the peptide. 
There are multiple steps that must be performed in order to create the 
MRM including 1) analysis of the protein sequence of interest to obtain a 
theoretical digestion profile, 2) empirical testing of digestion profile with a 
purified protein, 3) optimization of instrumentation parameters using 
synthetically developed peptide fragments, 4) development of the MRM using 
increased sample complexity, 5) isolation of in vivo experimental protein 
samples and mass spectrometry analysis.  Fig. 26 is a schematic 
representation of the experiments described in this Chapter and details the 
preliminary steps necessary for MRM method design.   
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Figure 26. Outline of the experiments described in this Chapter. 
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MRM experiments are usually performed using Liquid Chromatography 
(LC) coupled to Triple Quadrupole mass spectrometers. These types of 
instruments are designed to follow the work flow diagram depicted in Fig. 27. 
First, samples are injected in the chromatography column; typically a C18 
column which is made of an 18 carbon chain bound on a silica substrate. 
Peptides adsorb to the column and by gradually increasing the amount of 
polar solvent in the mobile phase they elute separately according to their 
biochemical characteristics. This step reduces the complexity of the sample 
prior to injection in the mass spectrometer. Second, ionization of the peptides 
is achieved by applying a high voltage to the peptides to create an aerosol 
with the electrospray ionization (ESI) probe. ESI does not fragment the 
peptides and can create multiply charged ions (z>1). Third, the ionized 
peptides move into the first quadrupole (Q1) and are analyzed by mass. 
Fourth, in the second quadrupole (Q2) the ions are collided with high pressure 
gas (argon) inducing dissociation of the ions in a process called collision 
induced dissociation (CID). Each ionized peptide that entered Q1 (precursor 
ion) will then be fragmented in Q2 into product ions that will be detected by 
Q3, which also analyzes each fragment by mass. The m/z values of precursor 
ions and product ions that will be generated after CID can be predicted based 
on the sequence for the peptide of interest. The collision induces breakage of 
the amide bond and loss of amino acids at the N- and C- termini of the 
peptide, and the resulting ions are called y- and b- ions. In MRM, the 
precursor ion of interest is selected in Q1 and the product ions of interest are 
monitored in Q3. MRM is an example of a targeted mass spectrometry 
approach, as this method only detects a selected peptide of interest. The 
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AQUA (absolute quantification) method was developed to directly quantify 
peptides using MRM [212]. Briefly, synthetic peptides of the same sequence 
as the peptide of interest are synthetized using a heavy labelled amino acid, 
shifting their mass by a known amount. These heavy peptides are used as 
internal standards and spiked with the unknown sample containing the light 
peptide of interest. The heavy peptides have the same retention time, 
ionization and fragmentation characteristics, but have a shift in mass which 
allows for comparison of intensity of endogenous (light) and heavy peptides.  
 
Figure 27. Schematic representation of the Triple Quadrupole mass 
spectrometer used for MRM. 
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RESULTS 
1) Analyze ERβ Sequence 
The first step in determining whether MRM is a feasible approach to 
detect and quantify ERβ phosphorylation is to analyze its sequence. Indeed it 
is necessary to enzymatically cleave proteins in smaller peptides that can be 
detected by Triple Quadrupole mass spectrometers for MRM experiments. 
Protein digestion is a common procedure in proteomics and several 
proteolytic enzymes are available commercially. Each protease has very 
specific cleavage sites; empirical digestion of the protein of interest can be 
tested using bioinformatics tools such as Expasy Peptide Cutter [213]. The 
size of the peptide of interest is also an important consideration for MRM 
experiments.  A maximum length of 25 amino acids is indicated for a few main 
reasons. First, mass of larger peptides is over the limit of detection of Triple 
Quadrupole mass spectrometers. Furthermore long peptides are typically 
unsuitable for synthesis. Finally amino acid side chains can potentially be 
modified during ionization and dissociation in the mass spectrometer, and 
longer sequences have more potential for modifications which would 
complicate the analysis. Another crucial factor when deciding which enzyme 
to use for digestion is the uniqueness of the sequence of the peptide of 
interest. Therefore, to avoid false positive results, it is essential to scan the 
NCBI database to confirm that the target peptide fragment is unique to the 
protein of interest. Finally, protease efficiency is high, however some cleavage 
sites are more optimal than others, and bioinformaticians have developed 
algorithms to predict  the likeliness of a “missed cleavage” to occur [214]. 
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 I performed the steps described above using the rERβ sequence 
available from Uniprot (accession number Q62986). The goal was to identify a 
protease that would digest ERβ containing the desired S87 and S105 sites in 
peptide fragments that met the optimal criteria for MRM. I first used Expasy 
peptide cutter to obtain ERβ digestion profiles for eight common proteases. 
Figure 28 shows the results of the theoretical digestion. The right column lists 
the cleavage sites for each proteases and I focused on proteases that cleaved 
the protein at residues close to S87 and S105. I calculated the size of the 
peptides containing S87 and S105 and evaluated my options. Arg-C, Asp-N, 
low-specificity-Chymotrypsin and Proteinase K were not feasible enzymes as 
they would not yield ERβ peptides I could use for MRM. Cleavage of ERβ with 
Lys-C or Lys-N yielded S87 and S105 containing fragments of 100 or 21 
amino acid length each. On average MRM experiments use peptide of 10 
amino acids, however it is possible to use peptides up to 25 amino acid long. 
Chymotrypsin digestion of ERβ generated a 43 amino acid peptide with S87 
and an 8 amino acid peptide with S105. Trypsin digestion resulted in a 33 
amino acid peptide encompassing S87 and a 7 amino acid peptide 
encompassing S105. This preliminary analysis revealed that none of the 
available enzymes would digest ERβ so that S87 would be contained in a 
fragment of the length required for MRM. This depends on the protein in the 
region surrounding S87, and makes the study of phosphorylation of S87 with 
the MRM approach unfeasible. However, as shown in chapter III, 
phosphorylation of S87 leads to more modest changes in ERβ function 
compared to S105, suggesting that phosphorylation at that site is less 
important in vivo. Furthermore, phosphorylated S105-ER was detected in 
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breast tissue samples and inhibited breast cancer cells invasiveness and 
migration [81]. Together, these data suggested that S105 was the best target 
for additional proteomics analysis and both high-specificity Chymostrypsin 
and Trypsin are feasible proteolytic enzymes (Fig. 28). Trypsin is the universal 
enzyme used in proteomics because it is readily available, economical, and 
several validated protocols are published. Furthermore, large data sets using 
mass spectrometry are available online allowing for preliminary identification 
about whether a protein of interest has been detected using similar 
techniques and most of the data collected used Trypsin digestion. Analysis of 
the available data sets showed that human and rat sequences are identical in 
the N-terminal region containing S105. Also, in vitro phosphorylated human 
ERβ at S105 was detected following tryptic digestion [81]. In that study, an 
Orbitrap mass spectrometer was used to detect the phosphorylated form of 
ER, but this was a positive indication that empirical tryptic digestion of ERβ 
would result in that peptide fragment (i.e. it is not a missed cleavage), and that 
the peptide can be ionized and detected using a mass spectrometer.  
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Fig. 28 Theoretical digestion of rERβ with 8 available enzymes. 
(PeptideCutter, Expasy.org) 
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 Next, analysis of the predicted ERβ tryptic digestion was done using 
PeptideMass, an Expasy bioinformatics tool, to analyze the mass of the 
peptide of interest. Common to most digestion protocols is the treatment of 
the samples with Dithiothreitol (DTT), a reducing agent, following by 
Iodacetamide, an alkylating reagent. The first step is necessary to convert 
cysteine side chains from disulfide bonds into free cysteine side chains. 
Iodacetamide treatment then alkylates the free sulfhydryl side chains adding a 
carbamidomethyl group (CAM), ensuring that no free sulfhydryl groups 
reform. These steps are necessary to allow for Trypsin’s full access to all 
cleavage sites and results in a 57.021 Da increase in mass to all cysteine 
containing peptides. Fig. 29, shows that following tryptic digestion of ERβ 
S105 results in a 7 amino acid peptide: SPWCEAR. The mass of the peptide 
is 905.3934 Da following CAM modification on the cysteine, which is ideal for 
detection using a Triple Quadrupole. This same peptide was detected, with 
the CAM modification, in the Lam et al. study, indicating successful digestion 
and modification [81].  
 While commercially available Trypsin is highly efficient, missed 
cleavage can occur. As explained earlier, missed cleavage probability can be 
predicted by algorithms created after analysis of all peptides that contain a 
missed cleavage in a large data repository (PeptideAtlas). Therefore, I tested 
the probability of missed cleavage upstream and downstream of the 
SPWCEAR sequence using the missed cleavage predictor program 
developed by King’s University [214], and the results are shown in Fig. 30. 
The right column indicates a score from 0-1, with the missed cleavages 
resulting in a higher score. Both N- and C- terminal cleavage sites have a 
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relatively low score, a positive indication that digestion with trypsin will 
successfully yield the target peptide containing S105. 
 Figure 29. Analysis of ERβ tryptic peptides (PeptideMass, Expasy.org). 
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Figure 30. Analysis of Tryptic digestion of ERβ for potential missed cleavage 
sites. (Missed Cleavage Predictor described in [214]).  
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2) Empirical ERβ digestion 
2a) Obtain recombinant ERβ 
While theoretical digestion analyses are the basis of all targeted 
mass spectrometry experiments, empirical digestion has to be 
performed before moving on with the synthesis of the heavy labelled 
peptides that will be used for the MRM. In collaboration with Mengjie 
Zhang, Research Specialist in Dr. Pieter de Tombe’s laboratory, I used 
an in vitro bacterial expression system to obtain large amounts of 
purified ER [215]. First, the rERβ sequence was cloned into the 
pEXP5-CT/TOPO expression vector, so that a 6histidine tag is co-
translated at the C-terminus of ERβ. In this vector, the T7 RNA 
polymerase necessary for translation of ERβ-His is under regulation of 
a Lac promoter. Therefore, induction with the lactose metabolite IPTG 
(Isopropyl β-D-1-thiogalactopyranoside) was required to obtain ERβ-
His6. BL21 DE3 competent cells were transformed with the ERβ-His6 
plasmid and plated overnight. Five colonies were picked and grown in 
liquid culture before being split into 2 aliquots. One of the aliquots (B) 
was induced with IPTG, the other (A), was not induced and served as 
the control. Following overnight incubation, cells were lysed and protein 
isolated. Screening of the colonies that most efficiently produced ERβ-
His6 after induction was done by analyzing Coomassie stained gels 
containing the protein. As seen in Fig. 31, IPTG induced samples 
showed a strong band at the expected 50KDa mass (see arrow), which 
was not present in the in control (IPTG-free = A) samples. Clone 5 had 
the highest intensity band, indicating a stronger induction of translation 
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of the ERβ-His6 protein, and was chosen for large-scale protein 
production. 
 
Figure 31. Screening of 5 clones following protein induction with IPTG. 
Protein visualized with Coomassie staining. Arrows indicate induced protein of 
the expected molecular weight of ERβ-His6.  
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Next, protein was isolated from 4 liters of bacterial culture and 
purified using a nickel affinity column that binds to the His6-tag of the 
ERβ-His6 protein. After binding to the column and a wash cycle, elution 
buffer containing Imidazole (which competes for binding to the nickel 
column) was added and eluted protein fractions were collected. The 
example in Fig. 32 shows protein fractions 12-21; as the arrow 
indicates, fraction 19 contained the target ERβ-His6 protein. Western 
blot analysis of the protein confirmed that both ERβ and the His-tag6 
were correctly translated (Fig. 33).    
 
Figure 32. Screening of eluted fractions 12-21 after IMAC. Protein visualized 
with Coomassie staining. Arrow indicates induced protein of the expected 
molecular weight of ERβ-His.   
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Figure 33. Representative Western blot staining of protein from the eluted 
fractions containing putative ER based on Coomassie stain. Membrane was 
incubated with primary antibody targeting N-terminal ER confirming 
expression at expected molecular weight.  
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2b) Recombinant ERβ digestion 
 Confirmation of the theoretical and previously published results were 
then accomplished by tryptic digestion of the recombinant ERβ-His6 protein 
(obtained by pooling and concentrating IMAC fractions) [81]. First, ERβ-His6 
protein was run on a SDS-PAGE gel and the gel band containing ERβ was 
excised, as well as a portion of the gel void of protein to be used as a 
negative control (see arrows in Fig. 34). Second, a standard in gel Trypsin 
digestion protocol was used to clean, reduce and alkylate the protein prior to 
an overnight incubation with Trypsin (see Methods for details). Digested 
peptides were then washed out from the gel and concentrated to a smaller 
volume using a SpeedVac centrifuge. The peptides were then mixed with a 
matrix (α-Cyano-4-hydroxycinnamic acid, CHCA) which facilities ionization in 
MALDI-TOF mass spectrometry (Matrix Assisted Laser Desorption ionization- 
Time of Flight).  Briefly, the samples mixed with the matrix are irradiated with 
a laser, causing the matrix together with the peptides to ionize and vaporize. 
Using an Axima-CFR Plus MALDI-TOF MS system in “reflecton mode”, the 
charged ions are reflected using an electrical field and are accelerated in a 
vacuum. The time of flight to the detector is dependent on the mass of the 
peptides. Therefore, using calibrants of known mass and measuring their 
TOF, it is possible to calculate the mass of the sample peptides. I used a 7-
point calibration curve and recalibrated the instrument between each sample. 
Repetitively, I was able to detect several expected tryptic peptides or ERβ, 
including the peptide of interest containing S105. Fig. 35 is an example of a 
spectrum acquired as described above. The y-axis shows the normalized % 
intensity of the ions and the x-axis shows the mass to charge ratio (m/z). 
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Importantly, only charged ions can be analyzed and detected by the mass 
spectrometer, hence the need of the matrix and laser bombardment.  The red 
and blue traces represent two separate duplicates of the in-gel digestion 
products of ERβ-His6 protein. The numbers indicate m/z of ions that were 
automatically detected by having high intensity. Indeed several of those, and 
others at lower m/z not showed in this example, match the mass of tryptic 
products of ERβ. Importantly a peak of 905.4 m/z is present in this example 
and others; this matches the mass of a singly charged SPWCEAR peptide 
containing S105. Ions are usually only singly charged in MALDI because it is 
a milder form of ionization compared to others such as ESI, which will be 
introduced in the next section. 
 The empirical digestion of ERβ-His6 protein with Trypsin successfully 
led to the peptide of interest containing S105. This process confirmed the 
theoretical results and the empirical results with the human form of ERβ [81]. 
These steps were necessary to evaluate whether the MRM approach would 
be feasible and the synthesis of target peptide would be necessary. 
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Figure 34. ERβ-His6 protein was run on a SDS-PAGE gel in duplicate and 
stained with Coomassie stain. Gel bands containing the protein of interest and 
a negative control were excised (See arrows). 
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Figure 35. Representative MALDI-TOF spectrum of gel digestion products of 
ERβ-His6. 
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3) Use target ERβ  peptides to develop the MRM 
The target SPWCEAR peptides required for development and 
validation of AQUA-MRM were synthesized by ThermoFisher Scientific 
with heavy Arginine which is 10 Da heavier due to the presence of C13 
and N15 isotopes.  Phosphorylated peptides were also synthetized in 
the light and heavy version (Fig. 36). 
 
 
Figure 36. Characteristics of the four SPWCEAR peptides purchased. 
  
Quality Certificate 
Sales Ordercode: KS35084
Production Ordercode FF40632
Posno Well_ID Barcode ID Peptide Name Solvent Nterm Peptide Sequence CTerm MW Amount [mg] Volume[µL] Conc[mg/mL] QC
1 A1 191257113 KS35084.1 ERB-light 50% ACN / 0,1%TFA [H] SPWCEAR [OH] 847.94 1.9 400 4.7 passed
2 A2 191257094 KS35084.2 pERB-light 50% ACN / 0,1%TFA [H] [S]PWCEAR [OH] 927.92 3.1 400 7.7 passed
3 A3 191266880 KS35084.3 ERB-Heavy 50% ACN / 0,1%TFA [H] SPWCEA(R) [OH] 857.87 1.5 400 3.7 passed
4 A4 191266891 KS35084.4 pERB-Heavy 50% ACN / 0,1%TFA [H] [S]PWCEA(R) [OH] 937.85 1.2 400 3.0 passed
12/1/2015 5:59
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 To develop a reliable MRM method, each peptide has to be tested for 
both its ionization and fragmentation characteristic. After electrospray the 
peptides can be multiply charged and the most prevalent ion form needs to be 
selected in Q1. Then the ion has to go through CID and the full spectrum of 
the product ions scanned. From all the product ions that are generated after 
dissociation, the most prevalent will be selected in Q3 in the MRM method.  
 The predicted y- and b- product ions of each peptide, can be obtained 
using bioinformatics tool such as MS-product, a program developed by the 
University of California. Fig. 37 shows the precursors and products m/z for the 
light and heavy SPWCEAR peptides. Note that the heavy peptide is 10m/z 
heavier that the light form in both the precursor and product ions that contain 
the heavy arginine. 
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Figure 37. Predicted precursor and product ions for the light and heavy 
unphosphorylated SPWCEAR peptide. 
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 A full scan analysis of each peptide, with no dissociation induced, 
shows which charged species are generated for each peptide. The spectrum 
in Fig.38 was collected from a directly infused short unphosphorylated light 
peptide. As indicated by the arrows, both the 1+ and 2+ species are 
generated. Because of the double charge the m/z of the 2+ species is equal to 
1/2 of the ion’s mass. The most prevalent species was the 2+ ion, and was 
selected in Q1 for the MRM experiment. For all four peptides the doubly 
charged ion was the most prevalent following electrospray ionization, 
therefore the 2+ ions was selected for fragmentation. 
 The subsequent step used Q3 to detect the full spectrum of product 
ions derived from dissociation of the 2+ precursor ions. Representative 
spectra of the light and heavy unphosphorylated peptides are shown in Fig. 
39. As indicated by the arrows, several of the predicted product ions were 
detected.  
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Figure 38. Spectrum for the SPWCEAR peptide. Arrows indicate the 1+ and 
2+ species. 
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Figure 39. Spectra detected in Q3 showing product ions of the 424.66 
(above) and 429.63 (below) precursor ions, the 2+ ion of the light 
unphosphorylated light (above) and heavy (below) peptides. Arrows indicate 
the m/z values that match the predicted products (for a list see Fig. 37). 
 
28
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 Collision energy (CE) applied in Q2 to induce ion dissociation must be 
optimized in order to determine that all of the precursor ions are dissociated 
into product ions. Optimal CE can be theoretically calculated, but then must 
be empirically verified. My results showed that the phosphorylated peptides 
required slightly higher energy for a complete dissociation, due to their larger 
size because of the 79Da addition of the phosphate, however efficient 
dissociation was obtained with similar CE.  
 In AQUA-MRM experiments, confident detection and quantification is 
best achieved through the use of four transitions (precursor and product ions 
pairs). In addition, the MRM method must be designed to target the CAM 
modified peptides to mimic the true MRM experiment, in which the peptides 
go through the trypsin digestion protocol. The four transitions that were highly 
reproducible and were chosen for the final MRM design are listed in Fig. 40. 
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Figure 40. List of transitions chosen for each target peptide. 
Protein Name Peptide Modified Sequence Ion Formula Precursor Mz Precursor Charge Product Mz Fragment Ion Product Charge Cleavage Aa
ERBETA SPWC[+57.1]EAR C38H56N12O12S 453.504846 2 721.30862 y5 1 W
ERBETA SPWC[+57.1]EAR C38H56N12O12S 453.504846 2 535.229307 y4 1 C
ERBETA SPWC[+57.1]EAR C38H56N12O12S 453.504846 2 375.198659 y3 1 E
ERBETA SPWC[+57.1]EAR C38H56N12O12S 453.504846 2 246.156066 y2 1 A
ERBETA SPWC[+57.1]EAR C38H56N12O12S 458.469178 2 731.316889 y5 1 W
ERBETA SPWC[+57.1]EAR C38H56N12O12S 458.469178 2 545.237576 y4 1 C
ERBETA SPWC[+57.1]EAR C38H56N12O12S 458.469178 2 385.206928 y3 1 E
ERBETA SPWC[+57.1]EAR C38H56N12O12S 458.469178 2 256.164335 y2 1 A
ERBETA S[+80]PWC[+57.1]EAR C38H57N12O15PS 493.494796 2 721.30862 y5 1 W
ERBETA S[+80]PWC[+57.1]EAR C38H57N12O15PS 493.494796 2 535.229307 y4 1 C
ERBETA S[+80]PWC[+57.1]EAR C38H57N12O15PS 493.494796 2 375.198659 y3 1 E
ERBETA S[+80]PWC[+57.1]EAR C38H57N12O15PS 493.494796 2 246.156066 y2 1 A
ERBETA S[+80]PWC[+57.1]EAR C38H57N12O15PS 498.459129 2 731.316889 y5 1 W
ERBETA S[+80]PWC[+57.1]EAR C38H57N12O15PS 498.459129 2 545.237576 y4 1 C
ERBETA S[+80]PWC[+57.1]EAR C38H57N12O15PS 498.459129 2 385.206928 y3 1 E
ERBETA S[+80]PWC[+57.1]EAR C38H57N12O15PS 498.459129 2 256.164335 y2 1 A
light 
unphosphorylated 
peptide
heavy 
unphosphorylated 
peptide
light 
phosphorylated 
peptide
heavy 
phosphorylated 
peptide
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4) Develop LC-MRM method 
 
The initial development of the MRM established the ionization and 
fragmentation characteristics of the pure peptides directly injected in the mass 
spectrometer by-passing the LC stage. However the final experiment is based 
on the ability of the endogenous (light) and exogenously added heavy 
peptides to be detected in a complex tissue protein sample following liquid 
chromatography. Therefore the LC step of the experiment must be optimized 
to determine the elution time of the peptide (i.e. retention time). During a LC-
MRM method, the instrument cycles through the list of defined transitions for 
the duration of the program. Using the Skyline software, created by the 
MacCoss lab at the University of Washington, the transitions acquired across 
time can be easily viewed. To first test the LC-MRM method, I mixed equal 
amounts of each peptide to detect each retention time and tested whether the 
transitions observed with the pure peptides were reproducible. 
Fig. 41 shows a screenshot of the Skyline software analysis of the LC-
MRM of the sample mix. On the left panel, each transition is highlighted and 
assigned a different color. The chromatogram shows a zoomed in window of 
the retention times at which the peptides eluted. The green and light orange 
traces represent the unphosphorylated light and heavy peptides which co-
elute. This result confirmed that the incorporation of the heavy arginine does 
not affect retention time. The red traces represent the phosphorylated 
peptides which also co-eluted as expected. Each peptide should only elute 
once, when the amount of organic solvent in the mobile phase is enough for 
the peptide to come off the C18 column and elute.  
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Figure 41. Chromatograph of the 4 pure peptides after LC-MRM program. On 
the x-axis is retention time, the y-axis is the signal intensity. For color legend 
see panel of the left. (Skyline software, MacCoss lab) 
 
Analysis of the intensity of each transition is also possible, and the 
prevalence of each product ion should be consistent across replicates. Fig. 42 
shows the four transitions monitored for the light unphosphorylated peptide in 
separate runs of the peptide alone (on the left) and mixed with the other 
peptides. As expected the pattern of each transition is conserved, with the 
245.15 product (in orange) being the more intense in both samples.
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Figure 42. The four transitions monitored for the light unphosphorylated 
peptide are shown in a run of the peptide alone (on the left) and mixed will all 
other peptides. Retention time and prevalence of each transition are 
conserved. 
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 After optimization of the LC-MRM and establishment of retention time 
for each peptide, a standard curve will be prepared using the heavy labeled 
peptides. LC-MRM of serial fold dilutions of the unphosphorylated and 
phosphorylated heavy peptide will be used for the standard curve. Using the 
Xcalibur software, the intensity of the area under the curve of each dilution will 
be plotted and fit to a linear curve. The standard curve will be used for 
quantification of light (endogenous) peptide in the experimental tissue 
samples. 
Perform MRM with experimental samples 
The LC-MRM method developed above will be used to measure the 
ratio of ERβ that is phosphorylated at S105 in the brain and heart of animals 
that underwent the estrogen deprivation paradigm. A known amount of the 
heavy peptide will be spiked with the tissue sample and, following LC-MRM, 
the ratio of the intensity of the endogenous peptide and the added heavy 
peptide will be calculated for both the phosphorylated and unphosphorylated 
peptides.  
Comparison of trypsin digestion of the unphosphorylated and 
phosphorylated peptide fragment. 
 The S105 of interest is directly downstream of the lysine residue 
recognized by trypsin in the cleavage site. It is possible that trypsin might not 
recognize and, therefore cleave, as efficiently when S105 is phosphorylated. 
To evaluate this possibility, I designed a longer peptide with 7 additional 
amino acids upstream of S105 (Fig.43). The heavy LYAEPQKSPWCEAR 
peptide was synthetized with and without phosphorylation of S105 and then 
tested using the same digestion parameters as the shorter peptide. The 
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results demonstrated that the heavy phosphorylated peptide was cleaved 
after successful digestion with trypsin (Fig. 44, left panel) and the retention 
time and most prevalent product ions were similar to the short peptide (Fig. 
44, right panel). 
 
Figure 43. The blue box highlights the longer peptide synthesize to study 
whether phosphorylation at S105 affects recognition and cleavage by Trypsin. 
 
 
  
132 
 
 
Figure 44. The long phosphorylated ERβ peptide (left) is successfully cleaved 
and yields transitions that match the short heavy phosphorylated peptide 
(right).
  
133 
DISCUSSION 
 In this chapter I have delineated the development of a LC-MRM 
experiment that can be used to detect and quantify phosphorylated ERβ. 
Optimization of the LC-MRM method is necessary before moving on to 
assaying the tissue samples, however I am confident that this experiment is 
the best approach to answer the fundamental next questions in this study. I 
have already demonstrated that phosphorylated ER is functionally distinct 
and alters downstream gene expression compared to the unphosphorylated 
form of the receptor (Chap. 3). Moreover, these functional differences are 
sensitive to the presence or absence of E2 in the cell, raising the possibility 
that ER differentially alters gene expression in postmenopausal women. 
Adding to this complexity, the activation of kinases that putatively 
phosphorylate ER is differentially altered by age and E2 in the brain and the 
heart (Chap. 4), thereby providing a mechanism for differential 
phosphorylation of ER with advanced age. The next step is to identify 
phosphorylated ER in the brain and heart of aged rats, and quantify changes 
in phosphorylation based on age and circulating levels of E2. These data will 
allow us to predict whether this functionally important modification is changed 
following longer deprivation of estrogen, and potentially is a basis for 
explaining the discrepant effects of E2 replacement therapy in 
postmenopausal women. 
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CHAPTER VI 
FINAL DISCUSSION 
SUMMARY OF KEY FINDINGS 
The aim of this dissertation was to uncover potential molecular 
mechanisms of the age related switch of estrogen treatment post menopause. 
The project stemmed from the clinical observations brought about from the 
Women’s Health Initiative study and the Timing Hypothesis. Important findings 
of the WHI were that the neurological and cardiovascular systems specifically 
benefit from E2 administration closely in time to the menopausal transition. 
The underlying hypothesis of this dissertation was that age and estrogen 
deprivation lead to altered kinase activation which could result in altered 
phosphorylation of ERβ in the brain and heart. 
The first goal was to test whether phosphorylation on ERβ would alter 
its activity as a transcription factor in neurons, where estrogens can be 
beneficial. Indeed the data presented in Chapter III show that phosphorylation 
of ERβ increases its activation of transcription at ERE sites, while abolishing 
the ligand independent inhibition of AP-1 sites (see Fig. 45).  These represent 
two very different modalities of ERβ activity as a transcription factor; the first 
requiring direct binding to the DNA at ERE sequences, the second by 
interacting with other transcription factors at the AP-1 sequences on the DNA.  
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Figure 45. Phosphorylation of ERβ at S105 increases ERE dependent 
transcription (above) and abolishes ligand independent inhibition of AP-1 sites 
(below).
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The possibility that phosphorylation of ERβ alters its ability to bind to 
the DNA at ERE sequences was also tested in Chapter III. The results 
showed that ERE binding is not altered when ERβ is phosphorylated in the N-
terminal domain which is not known to participate in this interaction. However, 
the N-terminal domain (pecifically S87 and S105) is important in mediating 
interactions with coregulatory proteins and participates in homo and 
heterodimerization.  
The Timing Hypothesis relates to the whole organism physiology, 
therefore aging and estrogen deprivation need to be investigated in vivo. The 
animal paradigm used in this study was designed to investigate the findings of 
the WHI study and the Timing Hypothesis. Briefly, aged female rats were 
ovariectomized to remove endogenous sources of estrogens. E2 or vehicle 
was administered after different lengths of time following the surgery. This 
design was chosen due to the clinical studies which showed that the 
beneficial effects of E2 depend on how long after menopause women started 
ET. The initial hypothesis that MAPKs are differentially activated depending 
on age and estrogen deprivation could be tested in this model. Indeed, 
measuring the activation of p38 and ERK, members of the MAPK family, 
revealed a clear interaction between length of estrogen deprivation and 
estrogen treatment. Namely, the length of time between ovariectomy and 
beginning of treatment resulted in altered effects of E2 on the activation of 
MAPKs. Among the striking results described in Chapter IV, are the clear 
brain region-specific and kinase-specific effects detected. Also, the factors of 
length of estrogen deprivation and E2 treatment showed significant 
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interactions, indicating that different effects of E2 treatment were 
detected depending on the time at which it was administered.  
 Additionally, in Chapter V this dissertation provides the description of a 
novel method for detecting and quantifying phosphorylated ERβ in vivo. The 
mass spectrometry technique described has been successful for the detection 
of lowly expressed proteins but has never been attempted to study ERβ. 
Indeed, because of the difficulties experienced in the use of antibody based 
assays, the MRM method described offers a reliable alternative. 
Taken together, the data presented in this dissertation demonstrate 
that alternative regulation of MAPKs signaling in the brain and heart could 
provide a novel mechanism explaining the variable effects of E2 following 
menopause. Furthermore, phosphorylated ERβ was detected in the heart and 
brain and the consequences of phosphorylation of ERβ on its regulation of 
transcription were determined. 
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PHOSPHORYLATION OF ERβ AND LIGAND INDEPENDENT ACTIONS 
The findings presented in Chapter III add to the renowned complexity 
of ERβ signaling. ERβ has been found to function completely differently from 
its cognate steroid receptor ERα. ERα binds to DNA and regulates 
transcription only in the presence of a ligand, as has been shown by ChIP-seq 
experiments in breast cancer cells [216]. Conversely, ERβ can bind to EREs 
in absence of ligand, with microarray data showing that ERβ regulates 
transcription of three classes of genes [70, 148, 217]. The first and larger 
class of genes was regulated by unliganded ERβ. The second class of genes 
was regulated only in the presence of ligand, and genes in the smaller third 
class were regulated by ERβ both in presence or absence of ligand. 
Interestingly, several of the Class I genes in the Vivar et al. study were 
enriched for AP-1 sites, demonstrating that unliganded ERβ targets genes 
under AP-1 regulation. This is important to consider in light of the results 
shown in Chapter III that the ligand independent inhibition of AP-1, which is 
characteristic of ERβ, was abolished when either phosphorylation site (S87 or 
S105) were mutated. This points to the possibility that the N-terminal domain 
is involved in ERβ interaction with a coregulatory protein or directly with 
transcription factor Jun/Fos that binds to the AP-1 DNA sequence. Mutation of 
either S87 or S105 abolished the ligand independent inhibition of AP-1 sites, 
indicating that the genes that Vivar et al. identified as Class I would not be 
regulated by phosphorylated ERβ. This could be a potential way of directing 
ERβ towards other sets of genes that do not have AP-1 sites in their 
promoters. Indeed we found that phosphorylation of ERβ at S105 increased 
ERE dependent transcription both in presence or absence of ligand. It is 
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possible that when unphosphorylated, ERβ regulates both Class I and 
Class II genes but after phosphorylation it is limited to Class II, ERE genes.  
As estrogen levels are low after menopause, ERβ is constantly 
functioning unliganded causing regulation of only Class I genes. Therefore it 
is possible that following menopause, in absence of estrogen, phosphorylation 
of ERβ would determine the set of genes it regulates. This modification would 
have critical consequences on ERβ signaling at a time when estrogen is low. 
PHOSPHORYLATION OF ERβ AND THE DYNAMIC STRUCTURE OF THE 
N- TERMINAL DOMAIN 
The dynamic structure of ERβ can also be the cause of the profound 
consequences of mutations of S87 and S105. The ligand binding domain and 
DNA binding domains of ERs have been described via X-ray crystallography 
in complex with ligands and ERE sequences respectively [218-224]. However, 
the three dimensional structure of the N- terminal domain of ERβ, along with 
many other nuclear receptors, has not yet been resolved. Indeed it has been 
shown that the AF-1 domains of nuclear receptors possess an intrinsically 
disordered (ID) conformation [225, 226]. The lack of particular structures has 
been attributed as the cause for the ability of nuclear receptors to interact with 
a variety of partners by easily changing structure to adapt and bind to a 
partner when the cellular milieu promotes that interaction. Both ERα and ERβ 
have an intrinsically disordered nature, however analysis of predicted 
secondary structural elements in the ER N-terminal domain shows that ERα 
has more α-helix and β-sheet elements than ERβ. The N-terminal domain of 
ERα contains 67% random coil conformation, whereas more than 80% of ERβ 
is unstructured. The possibility that an unstructured part of a transcription 
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factor becomes structured following interaction with a component of the 
transcriptional machinery or a coregulatory has been shown for nuclear 
receptors such as the glucocorticoid receptor and progesterone receptor [227-
229]. This is true for ERα as well, which by interacting with TBP (TATA 
binding protein) loses its disordered characteristics and becomes folded as 
shown by surface plasmon resonance and circular dichroism spectroscopy 
[225]. The same study was not able to replicate the experiments performed 
with the N-terminal domain of ERα with ERβ. This was attributed to the 
impossibility of ERβ to interact with TBP or the need for other proteins that 
form the transcriptional complex.  
 It is also possible that phosphorylation alters the intrinsically 
disordered nature of the N- terminal domain and determines the binding 
partners of ERβ. Much of what we know about the structure of the N- terminal 
domain of ERβ comes from sequence analysis prediction. The “Network 
Protein Sequence Analysis” for example, is a web service that was developed 
by a biocomputing team from analysis of sequence and structure information 
available in large databases [230]. Analysis of the N-terminal domain of ERβ 
with a prediction model shows that the biggest majority of it is unstructured 
and made of random coil (see Fig. 46) [231]. Strikingly the amino acids close 
to S87 form a short α-helix right next to an extended strand region, followed 
by a random coil and another short α-helix following S105. Intuitively, it is 
plausible to think that even a small change in this sequence at the interface of 
unstructured regions and short helices might result in large effects on the 
structure of the region. Furthermore, a modification such as phosphorylation 
that brings the addition of a negative charge could also result in a 
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conformational switch in the area. Changing S87 or S105 into Glutamic 
acid (E) would mimic the effect of the phosphate, as experimentally done in 
Chapter III, and could help obtain a prediction of the structural conformation of 
the N-terminal domain of ERβ following phosphorylation. Indeed when S87 
was changed into Glutamic acid, it destabilized the short α-helix close to the 
extended strand region and turned it into a random coil. Changing S105 into 
S105E had the opposite effect. Even if S105 is further away from the short 
helix than S87, S105E induces a conversion of the random coil into a helix 
(Fig. 46). This extends the α-helix from 5 to 8 amino acids; a longer α-helix 
could limit the dynamic movement of the region and direct ERβ towards 
interacting with one binding partner rather than another. As shown in Chapter 
III, phosphorylation of ERβ at S105 increased the ligand independent and 
ligand dependent activation of ERE dependent transcription which could result 
from the stabilization of the α-helix structure and the recruitment of the 
transcriptional machinery.  
It has been proposed that the unstructured and dynamic status of the 
N-terminal domain of ERβ is at the base of its heterogeneous function [210, 
226]. Phosphorylation in that region could result in different structural 
conformation leading ERβ to interact with a certain binding partner and 
therefore towards a specific function.
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Figure 46. Network Protein Sequence Analysis of the N-terminal domain of 
ERβ shows the conformational changes potentially induced by 
phosphorylation [230].  
 
wt ERβ
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PHOSPHORYLATION OF ERβ AND THE INTERACTING PROTEINS 
The interactome of ERβ is vast, depending on the tissue under 
analysis, and can be altered by hormone treatment in vitro [86, 87]. Indeed 
ERβ interacting proteins in the ventral hippocampus were altered by aging 
and E2 as shown by a study from our group [86]. It is possible that the 
observed changes in ERβ interacting proteins in E2 treated versus vehicle 
treated animals might be due to ERβ phosphorylation. As described above, 
phosphorylation could deeply alter the structure of the N-terminal domain 
which is known to mediate interactions with several proteins such as 
coregulators or TATA-binding proteins [128, 225, 232]. Furthermore, as 
described in Chapter IV, E2 treatment in the ventral hippocampus inhibits both 
ERK and p38 activity. This could cause decreased levels of phosphorylated 
ERβ and altered recruitment of interacting proteins, which serves as a 
potential explanation for the changes detected in the previous study. Many of 
the interactions of ERβ are transient and make determining the effect of 
phosphorylation on these interactions difficult.  An alternative approach to 
determine how phosphorylation of ERβ alters its interactome is using 
proteomics techniques such as APEX and BioID [233, 234]. These techniques 
are based on biotinylation of proteins proximal to the protein of interest which 
is tagged with a biotinylating enzyme. All biotinylated proteins have therefore 
interacted with the protein of interest and can be isolated using affinity 
chromatography. Mass spectrometry analysis is then used to reveal protein 
identity. While this is an in vitro approach to study if phosphorylated ERβ 
interacts with different proteins, it would potentially explain some of the 
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observed differences in its function.  
MAPKS IN THE AGING FEMALE BRAIN AND HEART 
Aging can be defined as “a progressive, generalized impairment of function, 
resulting in an increased vulnerability to environmental challenge and a 
growing risk of disease and death” [235]. Aging is a continuous process 
affecting the whole organism which is changed at all levels, from the 
molecular and cellular level to tissue and system levels. In women, 
reproductive aging is the decline in fertility that ends at menopause, when 
levels of circulating estrogens are low. The decline of circulating estrogens is 
accompanied by a decline in health and rise in neurological and 
cardiovascular disease [56, 58]. It is plausible to think that the concurrent 
aging and estrogen decline together lead to a continuous change in the brain 
and heart. Indeed the effects of ET are different depending on how long 
following menopause they are administered, indicating that something in the 
cellular milieu has changed. It was shown that there is a critical window at 
which estrogen can be protective, but the molecular basis for this change is 
unknown. It is also not understood whether there is one critical window for all 
systems or if estrogens might be beneficial for a larger span of time in one 
tissue or another. It was proposed that estrogen action has a “healthy cell 
bias”, meaning that if cells are healthy at time of estrogen exposure their 
response to estrogen will be beneficial [236]. In contrast, if estrogen is 
administered to a cell that is not healthy, estrogen will exacerbate the cellular 
stress. 
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Figure 47. Context dependent effects of Estrogen. 
 
The results shown in Chapter IV support the idea that the effects of 
estrogen treatment depend on the time of administration. Furthermore there is 
a clear difference between the results obtained in the heart and in the brain. In 
the brain E2 inhibited ERK activity; in the hypothalamus this was true at all 
times post OVX, in the hippocampus E2 was only effective 1 week post OVX. 
In the heart, however, E2 did not alter ERK or p38 at any time point. This 
differential regulation of MAPKs signaling could be indicating that the critical 
window of time is different for the brain and the heart, and indeed these two 
organs age differently. The brain is very sensitive to aging which is the biggest 
risk factor for neurodegenerative disease. The aging brain is characterized by 
underlying oxidative stress, neuroinflammation, glial activation, impaired 
protein processing and dysfunctional mitochondria [237]. The cardiovascular 
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system is also affected by aging which leads to atherosclerosis, thickening 
and loss of elasticity of the arterial walls, hypertrophy of the heart, and fibrosis 
[238].   
A POTENTIAL ROLE FOR PROTEIN PHOSPHATASES 
Protein phosphorylation is a reversible and transient mark placed by 
kinases and removed by phosphatases. These enzymes are part of a network 
that regulates cell signaling pathways and downstream effector proteins. In 
the last decade researches have started to focus their studies on the 
phosphatases that are responsible in removing the phosphorylation mark 
placed by kinases as a potential tool for drug development [239].  Indeed 
kinases are the target of several common medications for diseases such as 
diabetes, obesity, cancer etc. yet fewer phosphatase modulators are currently 
available [239]. Phosphatases can be broadly categorized based on their 
substrate recognition as protein Serine/Threonine phosphatases (PSTPs), 
Tyrosine phosphatases (PTPs) or dual-specificity phosphatases.   
Interestingly, phosphatases have been shown to be differentially expressed 
and activated by aging and hormonal status similar to many kinases  [240-
244]. A 2015 study showed that in primates aging significantly inhibited 
protein phosphatase 2A (PP2A) and consequently increased α-synuclein 
phosphorylation and oligomerization [243]. Similarly, STEP (Striatal-enriched 
Tyrosine phosphatase) is less active in the aged rats in several brain regions 
[242]. The activity of STEP has also been linked to age-associated neurologic 
disorders possibly because it is regulated by oxidative stress. Furthermore, 
the hormonal regulation of phosphatases is complex as previously discussed 
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for kinases. It was shown that both PSTPs and PTPs can be regulated 
by estrogen in healthy and cancer cells [244-248].  
The specific phosphatases that target ERβ’s S87 and S105 have not 
been investigated, but in vitro experiments could specifically identify which 
enzymes are responsible for removing the PTM placed by the MAPKs. It is 
plausible that these phosphatases are regulated by age and estrogen similarly 
to the results shown in Chapter IV for the MAPKs p38 and ERK. While it was 
not a focus of this dissertation, Tyrosine 36 has been recently identified as a 
phosphorylation site of ERβ [249]. Using in vitro and in vivo approaches T36 
phosphorylation was identified as a switch in determining the antitumor 
activity of ERβ in breast cancer. Indeed, phosphorylation of T36 was 
necessary for recruitment of coregulatory proteins at promoters of antitumor 
genes. Furthermore, the phosphatase EYA2 was shown to remove the 
phosphate mark placed by the kinase c-ABL. This is the first example of a 
well-defined signaling circuitry that regulates ERβ’s antitumor activity based 
on a specific phosphorylation mark. 
Identifying the phosphatases responsible for removal of 
phosphorylation at S87 and S105 and measuring its changes with age and 
estrogen are promising avenues that would complement and strengthen the 
data presented in Chapter IV. 
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MITOCHONDRIAL DYSFUNCTIONS WITH AGE AND ESTROGEN 
EFFECTS 
Known targets of estrogen regulation are mitochondria [250-255]. 
Interestingly mitochondrial dysfunction is common with age, and the 
“Mitochondrial theory of aging” proposes that the large amount of reactive 
oxygen species (ROS) produced in the mitochondria makes them a prime 
target for oxidative damage, which in turns decreases mitochondrial function 
and activates signaling pathways such as MAPKs [235, 256]. The three 
factors of aging, estrogen signaling and mitochondria are clearly intertwined 
and likely play an important role in the insurgence of the neurological and 
cardiovascular diseases associated with aging in women.  
Estrogen can regulate mitochondrial function both in a genomic way, 
by regulating transcription of mitochondrial proteins, and in a non-genomic 
way by regulating signaling pathways such as MAPKs that converge on 
mitochondria. Interestingly, two studies have looked at the mitochondrial 
proteome of the heart or the brain following estrogen treatment or estrogen 
deprivation via ovariectomy [257, 258]. The majority of the proteins that were 
altered by estrogen were involved with regulation of oxidative stress, 
apoptosis, and electron transport complex proteins. Furthermore, the 
respiratory rate and activity of respiratory chain enzymes were increased in 
brain mitochondria 24 hours following E2 treatment, indicating the possibility 
for either a genomic regulation of transcription of genes in those functions or a 
non-genomic activation of signaling pathways that led to regulation of 
mitochondrial respiration [259]. 
  
149 
Many of the beneficial effects of estrogen on mitochondria are thought 
to be due to ER dependent transcription of NRF-1, nuclear respiratory factor-1 
[260]. NRF-1 is a transcription factor that regulates transcription of 
mitochondrial genes in the nuclear DNA. Interestingly, the NRF-1 promoter 
has ERE and AP-1 sites in its promoter and both ERα and ERβ can induce its 
transcription [260, 261]. In breast cancer cells, it was found that unliganded 
ERβ represses the NRF-1 promoter via the AP-1 site, but E2 or Tamoxifen 
treatment relieves this repression [261]. An in vivo study E2 treatment in 
ovariectomized rats determined an increase in NRF-1 and several 
mitochondrial protein levels and enzymatic activity in mitochondria isolated 
from cerebral blood vessels [262]. The authors conclude that vasoprotection 
by estrogen treatment might be due to the measured improved mitochondrial 
function, improved respiration and reduced production of ROS.  
The non genomic effects of estrogens on mitochondria often include 
MAPKs signaling regulation. In in vitro experiments of human lens epithelial 
cells, E2 treatment reduced ROS produced by the mitochondria by activating 
ERK signaling which in turn stabilized the mitochondrial membrane potential 
[263]. Similarly, in cultured hippocampal neurons, brief E2 treatment reduced 
toxicity of elevated Glutamate which usually results in elevated Ca2+ [264]. 
Instead, brief E2 treatment increases the storage of Ca2+ in mitochondria and 
an elevation of the antiapoptotic gene Bcl2 [264]. In an in vitro model of AD, 
treatment with E2 inhibited the amyloid induced translocation of the 
proapoptotic protein Bax to the mitochondria and increased the antiapoptotic 
Bcl2 levels [265]. 
  
150 
This estrogen regulation of mitochondrial function via MAPKs has been 
identified in vivo as well. Exercise-induced myocardial hypertrophy is a 
physiological response to exercise that does not lead to fibrosis and is 
reversible. Interestingly females develop larger physiological hypertrophy 
which is proposed to contribute to the more favorable remodeling in response 
to pathological stimuli seen in females [266]. It was shown that exercise in 
females induces activation of ERK and p38 which phosphorylate transcription 
factors that activate expression of mitochondrial proteins, leading to increased 
mitochondrial mass to better cope with the increased size of myocytes. This 
process was not present in ERβ knockout mice, indicating that ERβ is 
necessary for the activation of MAPKs and improved response to exercise 
[266].  
As shown above, often the non-genomic effects of estrogen on 
mitochondrial function require activation of MAPKs which does not correlate 
with the results from our deprivation paradigm. In the hypothalamus, for 
example, E2 treatment strongly inhibited ERK at all time points. Does that 
mean that mitochondrial function is repressed in these samples? It is difficult 
to predict, because of the complexity of ERK signaling. However, if 
mitochondrial function was indeed reduced this could mean that the window 
for estrogen’s protective effects is closed in the hypothalamus. Interestingly in 
this brain region, longer deprivation caused stronger inhibition of ERK, 
possibly leading to an even worse phenotype. This could be an example of 
the “healthy cell bias”: longer deprivation from estrogen and aging could lead 
to unhealthier cells which more drastically respond to E2 treatment. In the 
heart both ERK and p38 were decreased by prolonged estrogen deprivation 
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and E2 treatment did not rescue this phenotype. This could again determine a 
failed protective response by E2, potentially due to altered cellular milieu. 
Because many of the protective effects of estrogen on mitochondrial functions 
are mediated by genomic regulation, it would be important to determine 
whether the NRF-1 transcription factor or the mitochondrial proteins known to 
be transcribed following estrogen treatment are increased in the E2 treated 
animals.  
In conclusion, the role of mitochondria in the beneficial effects of 
estrogens is known and could be a mechanism by which aging and estrogen 
together lead to time dependent effects. 
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FUTURE DIRECTIONS 
The studies presented here contribute to the understanding of estrogen 
receptor signaling and kinase regulation in the context of menopause. 
Importantly, these data support the ideas that post translational modifications 
alter ERβ’s functions and that the length of estrogen deprivation alone can 
affect the intracellular milieu of the aged brain and heart.  
There are many new possible lines of investigation brought about from 
these findings. First, the in vitro evaluation of the effects of ERβ 
phosphorylation on its activity as a transcription factor was a necessary 
starting point. While the abolished ligand independent activity of ERβ by 
mutation of either phosphorylation site was striking, the data presented do not 
provide an explanation for this change. The idea proposed above, that 
phosphorylation alters ERβ’s network of interactions, is compelling also due to 
the dynamic structure of ERβ near its phosphorylation sites. Using an in vitro 
approach such as BioID or APEX, the consequences of ERβ phosphorylation 
on its interaction with other proteins could be investigated [233, 234]. 
Furthermore the phosphorylation status of ERβ in vivo needs to be 
determined. The proteomics approach described in Chapter V will 
conclusively determine how phosphorylation of ERβ changes in vivo. This is 
crucial because of the results of Chapter III; namely ERβ’s regulation of 
transcription is altered by phosphorylation. Furthermore, in light of the results 
of Chapter IV, it is likely that phosphorylation of ERβ will be decreased in the 
brain and heart following E2 treatment, because ERK and p38 kinase were 
overall depressed. 
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 The other potential for investigation that is opened by these studies is 
the possibility that the altered MAPKs signaling after prolonged estrogen 
deprivation might result in mitochondrial dysfunctions. Indeed, I would 
hypothesize that following prolonged estrogen deprivation mitochondrial 
function in the brain and the heart would be reduced. Measuring mitochondrial 
function in the deprivation paradigm used here could be a meaningful 
assessment of cellular health. Furthermore, in vitro studies have shown that 
activation of MAPKs signaling is necessary for estrogen’s positive effects on 
mitochondrial function.  According to the data shown in Chapter IV, however, 
ERK and p38 were in general not activated by E2, suggesting that either 
MAPKs signaling is differentially regulated in vivo or potentially that the 
window of opportunity is closed in these tissues. Finally, the beneficial effects 
of E2 on mitochondrial function can be determined by increased NRF-1 levels 
which could be measured in the brain and heart in our deprivation paradigm. If 
the beneficial effects of E2 are mediated via the genomic pathway, NRF-1 will 
be increased, resulting in higher levels of mitochondrial proteins necessary for 
efficient mitochondrial respiration. 
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CHAPTER VIII 
BROAD CLINICAL IMPLICATIONS 
CLINICAL POTENTIAL OF ERΒ 
The Timing Hypothesis that resulted from the Women’s Health Initiative 
study is at the base of this dissertation work. Because of the age dependent 
effects of estrogen treatment in post-menopausal women physicians are often 
uncertain on whether it is a good option for their patients. Furthermore, the 
activation of ERα in the uterus or breast with estrogen treatment could lead to 
proliferation and cancer. This is often a concern of physicians and patients 
who decide to avoid ET. Therefore, ERβ selective agonists have been 
evaluated in the past 10 years, because ERβ does not induce reproductive 
tissue proliferation and is active in non-reproductive organs such as the brain 
and heart. For its neuroprotective and cardioprotective roles, ERβ is a 
potential target of regulation for age and menopause related diseases.  
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Figure 48. Potentials for ERβ specific treatment in post-menopausal women 
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NEED FOR BETTER UNDERSTANDING OF ERΒ SIGNALING 
A potential pitfall of using ERβ specific ligands in the clinic is that many 
aspects of ERβ signaling are still unknown. The characteristic ligand 
independent activity of ERβ in activating ERE dependent transcription and 
inhibiting AP-1 dependent transcription remains mostly unexplained. Indeed 
ERβ can interact with coregulatory proteins or transcription factors, bind to 
DNA and regulate transcription in absence of ligand. Furthermore while 
classically steroid receptors only translocate to the nucleus following ligand 
binding, ERβ can be found in the nucleus or other subcellular locations in 
absence of ligand. It is thought that the ligand independent functions of ERβ 
are particularly important after menopause when estrogens are low. Taking 
advantage of the functional and structural differences between ERα and ERβ 
several receptor specific ligands (SERMs) have been developed. ERβ specific 
botanical compounds known as phytoestrogens had been used for centuries 
in Chinese medicine. Different formulations of phytoestrogens have been 
tested in preclinical and clinical studies and have been deemed viable options 
for postmenopausal symptoms such as hot flashes, decreased memory 
function and menopause associated neurological decline [267-270]. Several 
phytoestrogens can bind to both ER isoforms, but selectively act on ERβ to 
induce recruitment of coregulatory proteins and activate transcription [271]. 
This selectivity ensures that ERα in reproductive tissues such as the breast 
and uterus is not activated and does not lead to proliferation and possibly 
cancer [271]. An approach used to limit ERα activation in postmenopausal 
women with breast cancer is to use Aromatase inhibitors [272]. Inhibition of 
aromatase leads to decreased circulating estrogens and reduced ERα 
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activation. Because ERβ can act in absence of ligand, use of Aromatase 
inhibitors could reduce endogenous estrogens thereby highlighting ligand 
independent actions of ERβ. More agreement on the beneficial effects of 
ERβ’s activation post menopause is leading to development of 
pharmaceuticals that take advantage of the growing understanding of ERβ’s 
to improve post-menopausal women’s life.  
Clinical and basic science studies have evaluated the use of SERMs 
on ERβ; however it is possible that following phosphorylation of ERβ 
treatment with SERMs does not lead to the same effects. Indeed in Chapter III 
I show that phosphorylation of ERβ alters its E2 dependent and independent 
regulation of transcription in neurons. It is a possibility that treatment with 
other ligands could have alternate effects. The results in Chapter IV show that 
MAPKs are differentially activated following estrogen deprivation and E2 
treatment which could correlate with altered levels of ERβ phosphorylation in 
vivo. While it is difficult to speculate on the physiological consequences of 
altered levels of phosphorylated ERβ in the brain and heart, in vitro  studies 
point out that a big effects would be the abolished ligand independent 
inhibition of AP-1 dependent transcription. This would result in increased 
transcription of the genes that are usually repressed by ERβ in absence of 
ligand when ERβ phosphorylation is high. The other important effect of ERβ 
phosphorylation was the increased activation of ERE dependent transcription. 
Taken together, increased phosphorylation of ERβ in vivo due to increased 
MAPKs activity would lead to a shift in its action from the inhibition of AP-1 to 
the activation of ERE.  
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A further complicating factor is that while only ERβ1 transcriptional 
regulation was tested in Chapter III, several splice variants exist. Interestingly 
all splice variants still include the N-terminal domain, therefore could be 
phosphorylated as ERβ1 is. Furthermore the human ERβ splice variants are 
truncated in the C-terminal domain, therefore lack the ligand binding domain. 
These ERβ splice variants can regulate transcription in absence of ligand, 
indicating that the N-terminal domain is necessary for its constitutive activity 
[70]. A recent study by our group detected ERβ2 splice variant, which has an 
insertion of 18 amino acids in the ligand binding domain, in the brain regions 
analyzed in Chapter IV [273]. Therefore it is possible that both ERβ1 and 
ERβ2 are differentially phosphorylated correlating with the altered MAPKs 
activation measured. Indeed more understanding on the dynamics of ERβ 
splicing and phosphorylation in the context of aging and estrogen deprivation 
might uncover a potential target for regulation. Drugs targeting splicing and 
phosphorylation are available, therefore understanding which splice variant 
and phosphorylation status are optimal for ERβ to have most benefits would 
be highly important for physicians.  
CLOSING REMARKS 
My findings shed light on the molecular characteristics of 
phosphorylated ERβ as well as highlighting the potential contribution of 
MAPKs signaling in the brain and heart in response to estrogen deprivation 
and E2. As predicted, I found that the cellular milieu of the aged brain and 
heart is altered by prolonged estrogen deprivation. While MAPKs signaling 
could affect brain and heart physiology through many critical cellular 
pathways, we found that when phosphorylated ERβ differentially activates 
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transcription. Therefore, if indeed MAPKs and consequently ERβ are 
differentially modulated by age and estrogen deprivation this could provide a 
molecular basis for altered response to ET. These findings highlight the need 
for further investigations on the effects of prolonged estrogen deprivation in 
post-menopausal women and provide a molecular explanation for the Timing 
Hypothesis.  
While the understanding of the molecular underpinnings of the Timing 
Hypothesis is still unclear, the clinical evidence that points toward the benefits 
of ET in post-menopausal women is strong. Studies enrolling large numbers 
of women and with the appropriate experimental design show that ET is 
neuroprotective and cardioprotective following menopause.  Furthermore, 
recent studies evaluating ERβ selective agonists are very encouraging and 
could remove the disadvantage of activating ERα in reproductive tissues. The 
societal and economical burden of post-menopausal issues ranging from hot 
flashes to dementia or atherosclerosis should serve as an incentive for 
doctors to prescribe ET to women, but at the right time (i.e. in 
perimenopause). In conclusion, I would recommend the use of ET to 
perimenopausal women, and I predict that soon ERβ specific agonists will 
have strong evidence in support of their use in the clinic.
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CHAPTER VIII 
GENERAL METHODS 
Ethics Statement 
Animal procedures were designed to minimize pain and suffering. All 
animal protocols were approved by the Institutional Animal Care and Use 
Committee (IACUC) at Loyola University Chicago, permit number 2009018. 
Animals and deprivation paradigm 
Female Fischer 344 rats were obtained from the National Institute of 
Aging (NIA) colony (Taconic) at 18 months (N = 80) of age. The animals were 
allowed to acclimate to the housing facility for 7 days after arrival. Animals 
were housed two per cage and were allowed free access to standard rat chow 
and tap water. One week after arrival, animals were deeply anesthetized with 
vaporized isoflurane and bilaterally ovariectomized (OVX). Briefly, the ovary 
and distal end of the uterine horn were pulled from the body cavity through a 1 
cm incision made through the skin and body wall. The uterine horn was 
clamped with a hemostat and ligated proximal to the clamp. The entire ovary 
and distal uterine horn were then removed. Animals were singly housed and 
provided with acetaminophen analgesic (122.7 mg/kg) in their water for 3 
days postoperative. 
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During this time, animals were weighed once/day and their water intake 
was measured. Following 3 days of analgesia the animals were pair-housed 
with their previous cage mate for the duration of the experiment. Following 
OVX animals recovered for 1, 4, 8, or 12 weeks (N=20/age group, Fig. 7). 
After the designated recovery time the animals were given a subcutaneous 
injection of either safflower oil (vehicle) (N=10/age group) or 2.5 μg/kg 17β-
estradiol (E2, N=10/age group) dissolved in safflower oil once/day for 3 days. 
This dose of E2 elevated levels in OVX female rats (56.5 ± 6.3 pg/ml, which is 
within physiological range of women who received hormone replacement 
therapy during post-menopause (17-75 pg/ml)[178]. Animals were euthanized 
24 hours after the last injection, trunk blood was collected, brain and heart 
rapidly removed and flash frozen.  
Tissue Collection 
The hypothalamus, dorsal and ventral hippocampus were microdissected 
using a Palkovit’s brain punch tool (Stoelting, Inc., Wood Dale, IL) according 
to “The Rat Brain in Stereotaxic coordinates” [274]. The left ventricle was also 
rapidly removed from heart that had been flash frozen and homogenized 
using silica beads and a Mini Beadbeater-8 (Biospec Products, Bartlesville 
OK). 
CHAPTER III METHODS 
PhosTagTM  Electrophoresis 
50 ug of dorsal hippocampus or heart (left ventricle) protein was run on 
precast  PhosTagTM Acrylamide 12.5% Acrylamide gels,  (Wako Pure 
Chemical Industries, Osaka, Japan). The gel was then transferred on a PVDF 
membrane (Promega, Madison WI), blocked for 1 hour with 5% BSA, then 
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incubated with the Estrogen receptor β antibody H150 (epitope: 1-150 
fragment of hERβ, N-terminal domain) (Santa Cruz, sc-8974, Dallas TX) at a 
1:250 dilution in 5% BSA TBST overnight. Blots were washed twice with 
TBST for 10 minutes prior to application of 1:5000 goat α-rabbit-HRP (Santa 
Cruz, sc-2004, Dallas TX) in 5% BSA TBST. Blots were washed twice with 
TBST for 10 minutes and imaged on the Bio-rad Chemidoc XRS+ imager 
(Bio-rad, Hercules, CA) using ECL Chemiluminescent substrate (Pierce 
Scientific, Rockford IL). Densitometry was performed using ImageLab 
software. Antibody specificity was confirmed with parallel Western Blots and 
PhosTagTM blots using ERα H-184 antibody (Santa Cruz, sc-7207, 1:1000 
dilution; data not shown). 
Alkaline Phosphatase treatment 
Specificity of phosphorylated proteins were confirmed by treating 50 µg of 
dorsal hippocampus protein (vehicle-treated animals) with 0, 30 or 60 units of 
alkaline phosphatase (Roche, Basel, Switzerland) for 2 hours at 37°C to 
dephosphorylate all phosphorylated proteins.  
Cell culture 
 The mouse hippocampal-derived cell line HT-22 (generously provided by Dr. 
David Schubert, Scripps Institute, San Diego, CA) was maintained in DMEM 
(Corning, Tewksbury, MA) containing 4.5% glucose and L-glutamine 
supplemented with 1x nonessential amino acids (Corning, Tewksbury, MA) 
and 10% fetal bovine serum (FBS) (Atlanta Biologicals, Norcross, GA). Cells 
were used at 70-80% confluency for all experiments.  
Hormone treatments 
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Cells at 70-80% confluency were rinsed with 1x PBS and then media replaced 
with phenol red-free DMEM plus 10% charcoal-stripped FBS (Atlanta 
Biologicals, Norcross, GA) at least 36 hours prior to hormone treatments in 
order to remove all exogenous hormone sources. 17β-estradiol (Sigma, St. 
Louis, MO) and 4-OH Tamoxifen (Sigma, St. Louis, MO) were diluted in 
molecular grade ethanol (EtOH) (Sigma, St. Louis, MO) and used at a final 
concentration of 100 nM as described previously [70, 136].   
Expression vectors and reporter constructs 
 Plasmid expression vector (pcDNA 3.0; Invitrogen, Carlsbad, CA) containing 
inserts for rER-β1 was provided by Dr. Tom Brown (Pfizer Corp., Cambridge, 
MA) and has been extensively characterized [8]. The ERE-tk-luciferase 
reporter construct (generously donated by Dr. Paul Budworth, Case Western 
Reserve University, Cleveland, OH) contains two repeats of the consensus 
vitellogenin ERE sequence upstream of the minimal thymidine kinase 
promoter-firefly luciferase (2xERE-tk-luc) in pGL2-basic plasmid (Promega, 
Madison, WI). The AP-1-tk-luciferase reporter construct (generously provided 
by Dr. Colin Clay, Colorado State University, Fort Collins, CO) contains three 
repeats of the AP-1 sequence into pGL2-basic plasmid. The renilla luciferase 
pGL4 reporter construct (Promega, Madison, WI) was used as an internal 
control for transfection efficiency.   
Site directed mutagenesis 
 The pcDNA3.0 plasmid expression vector (Invitrogen, Carlsbad, CA) 
containing a cDNA insert coding rat ERβ1 was mutated using the Quick 
Change II XL site-directed mutagenesis kit (Agilent, Santa Clara, CA) to 
create the phospho-mutants (see Table 1). Primers were designed using the 
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QuickChange primer design available from the Agilent website and point 
mutations were inserted following manufacturer’s instructions. Vectors were 
validated by DNA sequencing (ACGT, Inc, Wheeling, IL) to confirm successful 
site directed mutagenesis. 
Transient Transfections 
 HT-22 cells were plated at a density of 20000 cells /well in 96-well plates for 
48 h before transfection. Transfections were carried out using Fugene6 
(Roche, Basel, Switzerland) or Fugene9 (Roche, Basel, Switzerland) 
according to manufacturer’s instructions. Twenty-four hours after transfection, 
cells were washed with 1x PBS and incubated with dextran charcoal-stripped 
media containing hormone treatment or vehicle (EtOH) for 15 h and then 
lysed for luciferase assays. Transfection efficiency and expression was 
verified prior to luciferase experiments using GFP-tagged constructs (data not 
shown). 
Luciferase assays 
 Following lysis, control reporter (Renilla Luciferase) and reporter (Firefly 
Luciferase) activities were measured using the Dual-Luciferase Reporter 
Assay system (DLR; Promega, Madison, WI). Relative light units (RLU) were 
detected using a Biotek Synergy HT plate reader (Biotek, Winooski, VT) with 
automatic dual injector system and represented as a ratio of Firefly/Renilla 
Luciferase RLU. All experiments were conducted with 6 replicates for each 
condition in each 96 well plate and each assay was repeated in 4 or more 
independent experiments. 
Statistics 
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Two way ANOVA was performed to determine statistical significance and 
interaction between the groups followed by Tukey post hoc test for 
comparisons between mutants and wild type vector. Significance was set at P 
value < 0.05. All transfection data are represented as the mean percent 
change in fLUC/rLUC compared to vehicle-treated cells transfected with 
empty vector ± SEM. 
 
CHAPTER IV METHODS 
RNA Isolation 
Trizol reagent (Invitrogen, Carlsbad CA) was used to isolate total RNA from 
the hypothalamus, ventral hippocampus, dorsal hippocampus, and left 
ventricle of the heart. All RNA samples were quantified using Nanodrop 
spectrophotometry and analyzed for quality by visualization of the RNA on 
1.5% agarose gel.  
Quantitative reverse transcription PCR (RT-qPCR) 
Following RNA isolation, 1.0 µg total RNA was reverse transcribed using the 
SuperMix VILO cDNA synthesis kit for RT-qPCR (Invitrogen, Carlsbad, CA). 
Roche FastStart SYBR Green Master Mix was added to intron-spanning ERK 
and p38 primers: ERK forward: 5’CTCGGATTCCGCCATGAGAA3’, reverse: 
5’GGTCGCAGGTGGTGTTGATA3’; p38 forward: 
5’CAGGAAACGGGACGAACAGA3’, reverse: 
5’CCACAGAACTGCATGTCCCT3’. Then, 2 µL cDNA templates were added 
to duplicate reactions performed in 96 well plates. The following program was 
used for RT-qPCR: 1) 95°C for 10 minutes, 2) 95°C for 30 seconds, 3) 59°C 
for 30 seconds, 4) 72°C for 30 seconds, and melting curve analysis. All 
samples were normalized to the hypoxanthine guanine phosphoribosyl 
transferase 1 (HPRT) housekeeping gene (primers: forward: 
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5’AGCAGTACAGCCCCAAAATGG3’, reverse: 
5’TGCGCTCATCTTAGGCTTTGT3’), as it is not altered by E2 treatment [178, 
179]. Quantification of the target gene expression was achieved using the 
∆∆CT method [275].  
Protein Isolation 
Total protein was extracted from the hypothalamus, dorsal hippocampus and 
ventral hippocampus using T-Per reagent (ThermoFisher Scientific, Waltham 
MA) supplemented with Pierce Protease and Phosphatase Inhibitor Tablet, 
EDTA Free (ThermoFisher Scientific, Waltham MA). Similarly, total protein 
was extracted from the left ventricle of the heart using RIPA buffer 
supplemented with Pierce Protease and Phosphatase Inhibitor Tablet, EDTA 
Free (ThermoFisher Scientific, Waltham MA). Protein concentrations were 
measured using the Pierce BCA Protein Assay kit according to manufacturer’s 
directions (ThermoFisher Scientific, Waltham MA).  
Western Blot 
10 μg of isolated protein was electrophoresed on a 10% acrylamide gel. The 
gel was then transferred on a PVDF membrane (Promega, Madison WI), 
blocked for 1 hour with 5% Bovine Serum Albumin (BSA, ThermoFisher 
Scientific, Waltham MA) in Tris Buffered Saline with 0.1% Tween (TBST), 
then incubated with primary antibodies in 5% BSA TBST overnight (Table 4 – 
detailed antibody information). Blots were washed twice with TBST for 10 
minutes prior to application of a secondary antibody in 5% BSA TBST for 2 
hours, then blots were washed twice with TBST for 10 minutes and imaged 
using a Bio-rad Chemidoc XRS+ imager following application of the Pierce 
Enhanced Chemiluminescence (ECL) Western Blot substrate (ThermoFisher 
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Scientific, Waltham MA). PonceauS staining (MP Biomedicals,Santa Ana CA) 
was used to detect total protein. Quantification of bands was achieved by 
measuring the intensity of the bands following normalization to total protein 
with ImageLab software. Biological replicates were 6-8 per treatment/time 
point and samples were repeated in 2-3 technical replicates.  
 
 
Table 4. Details of antibodies used in Chapter V
Total ERK1/2 ERK1 antibody (K-23) sc-94,  Santa Cruz, Dallas TX Rabbit, polyclonal 1:500
Total p38α, p38β, p38γ p38 MAPK (D13E1)
8690S, Cell Signalling Techinology , 
Danvers MA
Rabbit, monoclonal 1:500
PhosphoERK1/2
Phospho-p44/42 MAPK 
(Erk1/2) 
(Thr202/Tyr204) 
9101s, Cell Signalling Techinology , 
Danvers MA
Rabbit, polyclonal 1:500
Phosphop38α, p38β, 
p38γ
Phospho-p38 MAPK 
(Thr180/Tyr182)
4511s, Cell Signalling Techinology , 
Danvers MA
Rabbit, monoclonal 1:500
Rabbit IgG
Anti-rabbit IgG, HRP-
linked 
7074s, Cell Signalling Techinology , 
Danvers MA
Goat, polyclonal 1:5000
Species raised in; mococlonocal or 
polyclonal
Peptide/Protein target Name of Antibody Catalog #, ,manufacturer
Dilution 
Used
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CHAPTER V METHODS 
 
Expression vectors and reporter constructs 
Rat ERβ sequence was cloned in the plasmid expression vector pEXP-
CT/TOPO (Invitrogen, Carlsbad, CA) using EcoRI (NEB, Ipswich, MA) 
restriction enzyme digestion.  The insertion was verified by sequencing which 
confirmed that 6His were inserted after the last amino acid of ERβ.  
Recombinant His-Tagged Protein Expression and Purification 
BL21 DE3 (generously donated by the Lab of Dr. de Tombe) competent cells 
were transformed with ERβ-6His plasmid DNA, and grown on LB-Amp plate 
overnight. Five colonies were picked for screening and grown in duplicates 
until culture turbidity reached OD600=0.4. Then IPTG was added to one 
duplicate (B, induced cells) of each colony to induce expression of ERβ-His6 
under control of the Lac promoter.  After additional incubation at 37°C for 5 
hours, cells were centrifuged and resuspended in Lysis Buffer. After 
sonication (10” pulses/4 times), supernatant was resuspended in Laemmli 
buffer, heated for 5” at 95°C and electrophoresed on a 4-15% acrylamide gel 
(Bio-rad, Hercules, CA).  The gel was then stained with 1% Coomassie R-
250, 10% Acetic Acid, 40% Methanol solution for 30’, destained for30” and 
imaged with Bio-rad Chemidoc XRS+ imager (Bio-rad, Hercules, CA). Based 
on the result, the highest expressing colture was inoculated in 10 ml of LB-
Amp. After overnight growth the large scale protein production started by 
inoculating 8 ml of the colture in 2 L of LB-Amp. The colture was then induced 
with IPTG and incubated at 37 °C. Cell pellet was then sonicated (30” 
pulses/4 times) and centrifuged at 10000rpm, 20’, 4°C. Supernatant was used 
for protein purification performed by Menjie Zhang (Dr. de Tombe lab) with an 
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automated FPLC system (AKTÄ FPLC, GE Healthcare). The sample was 
loaded on a HisTrap nickel affinity column (GE Healthcare). The column was 
then washed until ultraviolet absorbance at 280 nm reached equilibrium. ERβ-
His6 was then eluted using a buffer containing imidazole (which competes for 
binding the column) and the flow through was collected in separate fractions. 
Fractions were then electrophoresed and stained with Coomassie R-250 to 
verify which fractions contained ERβ-His6. The positive fractions were 
combined and concentrated using Pierce Protein Concentrator tubes (Pierce 
Scientific, Rockford IL). Protein concentration was measured using the Pierce 
BCA Protein Assay kit according to manufacturer’s directions (ThermoFisher 
Scientific, Waltham MA). To verify correct expression, ERβ-His6 protein was 
then electrophoresed on an Acrylamide 4-15% gels (Bio-rad, Hercules, CA).  
The gel was then transferred on a PVDF membrane (Promega, Madison WI), 
blocked for 1 hour with 5% BSA, then incubated with the Estrogen receptor β 
antibody H150 (epitope: 1-150 fragment of hERβ, N-terminal domain) (Santa 
Cruz, sc-8974, Dallas TX) at a 1:500 dilution in 5% BSA TBST overnight. Blot 
was washed twice with TBST for 10 minutes prior to application of 1:5000 
goat α-rabbit-HRP (Santa Cruz, sc-2004, Dallas TX) in 5% BSA TBST. Blot 
was washed twice with TBST for 10 minutes and imaged on the Bio-rad 
Chemidoc XRS+ imager (Bio-rad, Hercules, CA) using ECL 
Chemiluminescent substrate (Pierce Scientific, Rockford IL). After 
confirmation of ERβ-His6 expression, recombinant His- tagged protein was 
aliquoted and stored at -80 °C. 
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Tryptic digestion and MALDI-TOF analysis 
5 to 20 ug of Erbeta-His6 protein was electrophoresed on a 4-15% Acrylamide 
gel (Bio-rad, Hercules, CA). The gel was then stained with Coomassie G250 
(1% Coomassie G-250, 10% acetic acid, 40% Methanol) for 1 hour and 
destained overnight. The band corresponding to the ERβ-His6 protein was 
excised using a sterile scalpel; a negative control band with no protein was 
also excised. Gel bands were individually put in a 1.5 ml tube and washed 
with 50% Acetonitrile 50 % 100mM Ammonium Bicarbonate for 15’ at 37°C 
while shaking at 800 rpm. Then the “wash cycle” was performed. First bands 
were washed with a 100% 100mM Ammonium Bicarbonate for 15’ at 37°C 
while shaking at 800 rpm. Then they were washed with a 50% Acetonitrile 
50% 100mM Ammonium Bicarbonate solution for 15’ at 37°C while shaking at 
800 rpm. Then they were washed with 100% Acetonitrile for 15’ at 37°C while 
shaking at 800 rpm.  The gel bands were reduced using 10 mM DTT for 30’ at 
37°C while shaking at 550 rpm. The “wash cycle” was then repeated. Then 
gel bands were alkylated with 55mM Iodacetamide in 100 mM Ammonium 
Bicarbonate solution for 45’ at 37°C while shaking at 550 rpm. The “wash 
cycle” was then repeated. The gel bands were then treated with 1 ug of 
Trypsin on ice 1 hour, then overnight at 37°C while shaking at 550 rpm. The 
supernatant containing most digested peptides was saved. The gel bands 
were then washed according to the “wash cycle” to collect all possible 
remaining peptides from the gel. The washes were collected and pooled. 
Peptides were concentrated using a Speedvac. Peptides were then 
resuspeded in 0.1% Formic Acid.  
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The standard curve calibrants for MALDI-TOF and the peptides were then 
mixed with the α-Cyano-4-hydroxycinnamic acid matrix (CHCA) matrix 
(ThermoFisher Scientific, Waltham MA). The Axima-CFR Plus MALDI-TOF in 
reflecton mode was calibrated using a mix of the calibrants spotted on the 
target plate. Calibrants mix solution was pipetted next to each sample and 
calibration was repeated between each measurement.  
LC-MRM development 
A Thermo Scientific TSQ Vantage MS system was used for these 
experiments. The target peptides (SPWCEAR) were synthetized by 
ThermoFisher Scientific (Waltham MA) and used for the development of the 
MRM method. Peptides were resuspended in 50% Acetonitrile 0.1% Formic 
Acid to a 10picomle/ul concentration, aliquoted and stored at -80 °C. Peptides 
were diluted at 1picomol/ul and full scan was collected after direct injection of 
5ul. Parent ions were then detected and identified. The 2+ parent ion was 
then selected for fragmentation and a full MS/MS scan was collected. Four 
transitions (precursor-product ions combinations) were picked for each 
peptide to be used for the MRM method. The MRM method was prepared 
using the Xcalibur software (ThermoFisher Scientific, Waltham MA). Peptides 
were combined in equal amounts and injected through in a Biobasic C18 
HPLC column (ThermoFisher Scientific, Waltham MA) in a 66 minutes long 
LC-MRM method.  The MS/MS spectra collected were analyzed using the 
Skyline software, created by the MacCoss lab at the University of 
Washington.  
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